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ABSTRACT 
BACKGROUND AND OBJECTIVES: Streptococcus agalactiae (Group B Streptococcus, 
GBS) is the leading cause of neonatal infections and deaths in human. It can also cause 
infections in pregnant women and non-pregnant adults. Penicillin and ampicillin are 
antibiotics of choice for the treatment of GBS infections. Erythromycin and clindamycin are 
used as alternative therapy in penicillin allergic patients, however resistance to these agents 
has been increasingly observed. This present study was undertaken to determine the 
colonization rate of GBS, susceptibility profile and the mechanism of antibiotic resistance in 
pregnant women and their babies at Dr. George Mukhari Academic Hospital in Pretoria. 
 
METHODS: Rectal and vaginal swabs were collected from pregnant women; ear and 
umbilical swabs from newborns over an 11 month period. Samples were cultured on 
selective media (CNA agar and Todd-Hewitt broth) and GBS positively identified using 
morphological and biochemical tests including Gram staining, hemolytic activity, catalase 
test, bile esculin, CAMP test and Latex agglutination test. The susceptibility testing was done 
using the Kirby-Bauer and E-test methods. The D-test method was used to determine the 
inducible clindamycin resistance. Multiplex PCR with were used to detect different genes 
coding for resistance. 
 
RESULTS: Out of the 413 patients evaluated, 128 (30.9%) were positive with GBS. All 
isolates were sensitive to penicillin and ampicillin. Erythromycin and clindamycin resistance 
was 21.1% and 17.2% respectively; of which 69% harbouring constitutive MLBB, 17.4% 
inducible MLSB. The alteration of ribosomal target encoded by ermB genes was the 
commonest mechanism of resistance observed in 55% of isolates, 38% of isolates had both  
ermB and linB genes and efflux pump mediated by mefA genes was detected in one of 
isolates. 
 
Conclusion: This study reaffirms the appropriateness of penicillin as the antibiotic of choice 
for treating GBS infection. However it raises the challenges of resistance to the macrolides 
and lincosamides. More GBS treatment options for penicillin allergic patients need to be 
researched. 
 
Keys terms  
Group B streptococcus (GBS); antibiotic susceptibility; antibiotic resistance; gene of 
resistance; mechanism of resistance; Multiplex polymerase chain reaction; pregnant women; 
newborn babies; Pretoria, South Africa. 
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 CHAPTER I 
INTRODUCTION 
 
1.0 Brief Introduction 
Streptococcus agalactiae (Group B Streptococcus; GBS) was recognized primarily 
as an important cause of bovine mastitis. However, since the 1970s, GBS has 
become the leading cause of neonatal infections in humans and an important cause 
of illness in pregnant women, the elderly, and adults with underlying diseases such 
as diabetes (Lammler et al., 1995; Murayama et al., 2009). GBS forms part of normal 
flora of the gastrointestinal and genital tract and is found in 10 – 40% of pregnant 
women (Mandell et al., 2010; Manning et al., 2003).  
 
Colonization rate differs among ethnic groups, geographic area, and ages; however, 
rates are almost similar for pregnant and non - pregnant women (Dzowela et al., 
2005; Mavenyengwa et al., 2010, CDC 2010). Different GBS colonization rates have 
been reported in African; Zimbabwe (32%), Gambia (22%), Nigeria (20%), Ivory 
Coast (19%), and 16.5% in Malawi (Dzowela et al., 2005). In Tanzania, maternal 
colonization of GBS was confirmed in 23% of pregnant women (Joachim et al., 
2009). In a South African study, GBS colonization rate of 21.5% was reported 
(Madzivhandila et al., 2011). GBS prevalence has been shown to be higher in 
African countries   and studies show that black race, poor socio-economic status of 
women  are usually implicated among the risk factors for GBS colonization (Schrag 
et al., 2002; Dzowela et al., 2005; Edmond et al., 2012).  
 
The incidence of GBS disease ranges from 0.5 to > 2 per 1000 live births in different 
geographic areas (Fisher et al., 2001; Lyytikäinen et al., 2003; Yu et al., 2011; 
Edmond et al., 2012). Several reports on the incidence of GBS infection have been 
documented; 2.7 per 1000 live-births in Aberdeen - Scotland (Skinner et al., 1978); 
0.72 per 1000 live-births in UK and Republic of Ireland (Heath et al., 2004).  
 
In USA, due to the CDC’s Active Bacterial Core surveillance (ABCs) in the emerging 
infection program network, reliable epidemiologic data on invasive infection due to 
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GBS were obtained for a population of 17 million people during 1999 to 2003. GBS 
infection resulted in about 20,400 cases and 2,200 deaths with the incidence of 1.7 
infants per 1000 live births. The highest attack rates were observed for patients less 
than 1 year and + 65 years old (Murray et al., 2007; CDC, 2009). However in recent 
years, with the application of high prevention efforts, this incidence of GBS 
dramatically declined from 1.7 cases per 1,000 live births to 0.34–0.37 cases per 
1,000 live births. GBS caused approximately 1,200 cases of early-onset invasive 
disease per year; and approximately 70% of cases were among babies born at term 
or ≥37 weeks’ gestation (CDC, 2010).  
 
In Malawi, the incidence of GBS infections of 0.90 per 1000 live-births was reported 
(Gray et al., 2007). In South Africa, the first report of GBS infections in neonates was 
reported in Kwazulu Natal, and the incidence was reported to be 2.65 per 1000 live 
births (Haffejee et al., 1991).  
 
1.1 Morphology and Growth conditions 
The species Streptococcus agalactiae is a Gram positive bacterium,  coccoid  in 
shape, catalase negative, encapsulated, facultative anaerobe, with β-hemolysis on 
blood containing agar and gives a positive CAMP test (Willey et al., 2011). GBS 
grow on most bacteriologic media and occur predominantly in pairs and in chains 
formation (Figure 1). Encapsulation may be evident in direct smears of purulent 
exudates. On 5% sheep blood agar, GBS produces smooth large gray to whitish-
gray colonies of > 0.5mm, and surrounded by hazy, a weak zone of β-hemolysis of 
red blood cells in the culture medium. However, the use of enriched selective media 
(CNA agar and Todd-Hewitt broth) for 18-24 hours remains critical for the sensitivity 
of GBS culture results. Sensitivity increases by approximately 50% with use of 
enrichment media (CDC, 2010; Farley et al., 2001; Willey et al., 2011).   
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   Figure 1. Streptococcus agalactiae ATCC(R) 13813 (Cat. no A300; adapted from Catalog.hardydiagnostic.com)   
 
1.2 Transmission 
Mother to child transmission, vertical transmission, commonly occurs via the 
ascending route from the maternal genital tract into the amniotic fluid, which is then 
aspirated by infant in utero or at delivery (Baker et al., 1974; Moyo et al., 2002). 
Predisposing factors include birth complication, stillbirth, prolonged rupture of 
membrane (or difficult labor) and lack of antibodies to the invading GBS strain in the 
mother and hence the neonate (Bottone, 2004; Greenwood et al., 2007).  
  
Neonatal GBS infection is classified as early-onset disease (EOD), when occurring 
within 12h – 6 days after birth (70% - 80% of cases); and late-onset disease (LOD), 
when it occurs more than 7 - 90 days after birth and the childhood onset disease 
(COD, age > 90 days). Late-onset disease is transmitted from mother, day care or 
health care personnel to infants (Madhi et al., 2003; Martins et al., 2011). The aspect 
of infections beyond early Infancy is often used for patients with GBS diseases and 
who are older than 3 months and younger than 18 years old. Many of these 
infections are rare and occur among very low birth weight infants (Mandell et al., 
2010). 
In adults, GBS is a part of normal flora of the gut and genital tract and found in both 
male and female. Due to the diverse obstetric complications and manipulations, the 
bacteria can become active and be transmitted. In elderly people the bacteria can be 
transmitted from one person to another during a long stay in hospital and nursing 
facility residents (Narayanan et al., in 2006) 
 
4 
 
1.3 Frequency of Antibiotic Resistance in GBS 
Antibiotic resistance is the ability of bacteria or other microbes to resist the effects of 
an antibiotic. It occurs when bacteria change in a way that reduces or eliminates the 
effectiveness of drugs, chemicals, or other agents designed to cure or prevent 
infections. The bacteria survive and continue to multiply causing more harm (Beith et 
al., 2008).  
 
Antibiotic resistance has actually become a serious public health problem worldwide. 
However, a large part of the problem is due to the massive use or misuse of 
antibiotics in the biosphere which has had serious consequences for the antibiotic 
guidelines for the treatment of infections (Greenwood et al., 2007; Beith et al., 2008). 
Evolution of bacteria towards resistance has been considerably accelerated by 
selective pressure exerted by over prescription of drugs in clinical settings; self-
medication; inappropriate antibiotic treatment; the failure of taking the entire 
prescribed course of antibiotics; and the use of antibiotics to treat viral infections. 
Those are among other factors that promote emergence of antibiotic resistance 
(Walsh et al., 2003; Beith et al., 2008).  
 
Several studies, carried out at various centers around the world, have assessed the 
antimicrobial susceptibility profile and determined the mechanism of resistance in 
GBS. These studies, in accordance with CDC 2010 guidelines, found that penicillin is 
the antibiotic of choice for the treatment of GBS infections, followed by ampicillin and 
the 1st generation cephalosporins (Law et al., 2005; CDC, 2010); and have reported 
that there is an increase worldwide in the resistance to two most commonly used 
antibiotics for penicillin allergic patients with high risk of anaphylaxis namely 
macrolides (erythromycin) and linconsamide (clindamycin), living no alternative 
drugs for penicillin-allergic individual (Pearlman et al., 1998; Arpin et al., 1999; 
Ghearrhadi et al., 2007; Culebras et al., 2002; Malbruny et al., 2004; Betrui et al., 
2004; Wehbeh et al., 2005; Dipersio et al., 2006).  
The erythromycin resistance mechanism in GBS is mostly due to ribosomal 
modification encoded by erm genes (Arpin et al., 1999; Zeng et al., 2006, Gygax et 
al., 2007) and Clindamycin resistance in GBS is due to ribosomal translocation 
encoded by linB genes (Heelan et al., 2004).  
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It has been shown by various studies that erythromycin and clindamycin resistance 
has been the most frequently observed among GBS. This resistance has been 
observed in both developed and developing countries (Dahesh et al., 2008). A recent 
study in Italy, by Lambiase et al., 2012, reported a higher resistance to both 
erythromycin and clindamycin; ranging from 16.5% to 69.9% in the 4 years study 
period (from 2005 to 2008). They concluded that this increase of in vitro resistance of 
GBS to macrolides and clindamycin was clearly evident and suggested that the 
discordance with reports from different countries emphasizes the crucial role of 
microbiological methods in setting possible therapeutic strategies. 
 
In Japan, macrolide-resistant strains were detected in both children and adults and 
the difference was statistically significant different, with the majority resistance being 
due to erm(B) genes. One of the collected strains had mutations of the pbp2x gene, 
responsible for reduced penicillin susceptibility in GBS (Murayama et al., 2009).  
 
Simoes et al., 2004, in USA, determined the in vitro resistance of GBS to 12 
antibiotics currently used for GBS chemoprophylaxis in pregnant women. In which 
25% of isolates were resistant to erythromycin and 19% resistant to clindamycin. In 
France, the level of erythromycin and clindamycin resistance from GBS isolates was 
a concern and led to the recommendation that alternative prophylactic therapy for 
pregnant women who are allergic to penicillin should be guided by susceptibility 
testing (De Mouy et al., 2001).  
 
To establish the susceptibility of Zimbabwean GBS strains isolated from hospitalized 
patients, a study was performed in four regions of this country. One hundred percent 
of isolates showed resistance to tetracycline, 14% to erythromycin, 8% to 
clindamycin and 2% of isolates showed intermediate susceptibility to penicillin (Moyo 
et al., 2001).  In Malawi, serotype Ia and III were reported to be responsible for 77% 
of disease. All isolates were susceptible to penicillin, but 21% were resistant to 
erythromycin (Gray et al., 2007). In Tanzania, the study performed in Dar es Salaam 
has shown a resistance rate to clindamycin and erythromycin of 17.6% and 13% 
respectively (Joachim et al., 2009). 
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Several other studies have been carried out to assess the resistance patterns. 
However these results cannot be used to compare with other areas due to difference 
in study design and also difference in geographic region (Berkowitz et al., 1990; 
Chohan et al., 2005). 
 
The mechanisms of resistance of GBS to these antibiotics are well known. 
Numerous molecular methods such as Multiplex PCR, Quantitative real-time PCR 
and Individual gene specific PCR have come to the fore in detection of genes of 
resistance in GBS (Gygax et al., 2006; Brochet et al., 2007; Kimura et al., 2008; 
Gosiewski et al., 2012). 
 
1.4 Rational and Motivation 
This study aimed to investigate the incidence of antibiotic resistance of GBS isolates 
at Dr. George Mukhari Academic Hospital (DGMAH) in Pretoria. GBS antibiotic 
susceptibility surveys demonstrate increasing prevalence of resistance to alternative 
drugs (erythromycin and clindamycin) used for penicillin allergic patients (Back et al., 
2012). Because of various mechanisms employed by GBS to counteract the effects 
of these therapeutic agents, and if steps are not taken to prevent it, antibiotic 
resistance in GBS will reach an era where all antibiotics might be rendered 
ineffective (Fitoussi et al., 2001), creating a situation similar to the pre-antibiotic era. 
Hence, routine surveillance, susceptibility profiles of GBS to these antibiotics as well 
as understanding of resistance mechanisms are warranted.  
 
In South Africa, this organism has received minimal attention; and thus local data 
that seek to investigate the incidence of antibiotic resistance in GBS infections are 
scanty in our setting. Therefore the purpose of this study was to determine the 
colonization rate of GBS disease, antibiogram, antibiotic resistance and molecular 
basis of resistance of GBS isolates from pregnant women and their newborns at Dr. 
George Mukhari Academic Hospital, in Pretoria. 
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1.5 Aims and Objectives of the study 
1.5.1 Aim 
The aim of this study was to determine the anti-biogram and mechanisms of 
antimicrobial resistance in GBS isolates from pregnant women and their newborns at 
Dr. George Mukhari Academic Hospital (DGMAH), in Ga-rankuwa, Pretoria. 
1.5.2 Objectives 
- To determine the colonization rates of GBS isolates from pregnant women 
and their babies at DGMAH 
 
- To assess the susceptibility profile of GBS isolates to penicillin, erythromycin, 
clindamycin, ampicillin, high level gentamicin, vancomycin, chloramphenicol, 
tetracycline and ciprofloxacin. 
 
- To determine genetic basis of resistance in GBS isolates colonizing pregnant 
women and their babies at DGMAH. 
 
- To determine the mechanisms of antibiotic resistance (erythromycin and 
clindamycin) in GBS isolates from pregnant women and their babies at 
DGMAH. 
 
1.6 Significance of the study  
This study will provide baseline information on prevalence, antibiotic susceptibility 
and resistance profiles of GBS in pregnant women and their newborns at Dr. George 
Mukhari Academic Hospital, Pretoria.  
 
Data on antibiogram and molecular profiles will be useful as a source of information 
to guide good management of patients, treatment regiment design, routine 
surveillance of antibiotic resistance patterns, and also will help to raise awareness 
and inform policy on prevention against GBS infections in newborns born to 
colonized mothers; and will provide templates for practical epidemiological 
application. 
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CHAPTER II 
LITERATURE REVIEW 
2.1 Classification of Streptococci 
The genus Streptococcus, of the family Streptococacceae, is comprised of diverse 
group of facultatively anaerobic to strictly anaerobic species; and divided into three 
genera, Streptococcus, Enterococcus and Lactococcus (Willey et al., 2011). The 
genus Streptococcus includes different species such as S. agalactiae, S. anginosus, 
S. bovis, S. canis, S. constellatus, S. cristatus, S. dysagalactiae, S. equi, S. equines, 
S. gordonii, S. milleri, S. mitis, S. mutans, S. oralis, S. parasanguis, S. pneumonia, 
S. porcinus,   S. pyogenes, S. ratti, S. salivarius, S. sanguinis, S. sobrinus, S. suis, 
S. Uberis, S. vestibularis (Willey et al., 2011). 
  
They have been classified on the basis of the colony size, the interaction with 
erythrocytes in agar media as α-hemolytic (greening due to hemoglobin conversion), 
β-hemolytic (clear zone of hemolysis around colonies) and γ-hemolytic (no zone); 
and the presence of Lancefield antigens. The taxonomy of Streptococci has 
experienced a number of changes during the last 20 years due to the application of 
molecular biology techniques such as 16S rRNA gene sequencing; and DNA – DNA 
re-association experiments; and still source and object of different studies. However, 
the traditional streptococcal classification system is well established and still of value 
to the clinical microbiologist (Murray et al., 2007).   
 
Differentiating GBS strains by phenotypic molecular techniques, such as serotyping 
enabled the earliest molecular epidemiologic studies to be conducted. Recently, 
genotypic techniques, such as pulsed-field gel electrophoresis (PFGE) and 
nucleotide sequence analyses have been utilized to better characterize the GBS 
strains in circulation, and to gain a better understanding of disease pathogenesis, 
and possible transmission modes (Murray et al., 2007; Willey et al., 2011). 
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Figure 2 below shows the general scheme for the classification and identification of 
streptococci. 
 
 
Shape 
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                 Growth in presence of oxygen 
                      -  
 Anaerobe cocci     +     
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       -           + 
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     +                 - 
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                 +         - 
 
                         Hemolysis 
          
                           α   β 
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 +              - 
                                      CAMP  reaction 
        +   - 
                                              +     - 
                                   Other Lancefield 
Source: Willey et al., 2011 
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S. pneumoniae 
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2.2 Isolation and Screening of GBS 
GBS can be isolated from blood, cerebrospinal fluid ( CSF), urine, vagina, rectal 
and/ or site of local suppuration. The reliable detection of colonization with GBS in 
pregnant women before delivery is an essential requirement for effective prophylaxis 
(Narayanan et al., 2006). 
 
Screening for GBS consists of obtaining and identifying by culturing vaginal and anal 
specimens at 35 to 37 weeks’ gestation. The mother’s vaginal and ano-rectal swabs 
are collected and placed into an appropriate transport medium such as Amie’s or 
Stuart; streaked on a single 5% defibrinated sheep blood agar plates containing 
antibiotics such as Columbia colistin and nalidixic acid (CNA), and inoculated into 
selective broth media, such as Lim broth or Todd-Hewitt broth, with the same 
antibiotics and similar concentration as CNA agar, and incubated for 24hours in a 
CO2 enriched environment. The broth culture be sub-cultured onto blood agar and 
plates read after 24- 48 hours (Bergeron et al., 2000; Manning et al., 2003; CDC, 
2010 ). 
 
Colonization with GBS in pregnant women can be identified rapidly, accurately and 
reliably by molecular assays such as PCR for prenatal, nucleic acid amplification test 
(NAAT) etc. The performance of these tests allows for rapid intrapartum detection of 
GBS in 45 - 100 minutes before delivery (Bergeron et al., 2000; Manning et al., 2003; 
Bergseng et al., 2007; CDC, 2010) 
 
2.3 Typing of GBS 
Group B Streptococci are identified because of their content of rhamnose-containing 
―group specific‖ polysaccharide. The capsule of the organism is composed primarily 
of a sialic acid containing type-specific polysaccharide, which is the basis for further 
classification (Chan et al., 2000). The pathogenesis of GBS can be grouped into the 
adherence to epithelial surfaces, penetration of host cellular barrier, avoidance of 
immunologic clearance mechanisms and inflammatory activation (Musa et al., 2012).  
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The Lancefield classification scheme serologically groups β-hemolytic streptococci 
on the basis of their carbohydrate cell wall antigens; this differs from typing of group 
A streptococci for which protein antigens are utilized (Lammler et al., 1995; De 
Azavedo et al., 1999). To date, based on the polysaccharide antigen, ten capsular 
types of GBS have been described (Ia, Ib, II, III, IV, V, VI, VII, VIII and IX); and in 
several reports, capsular types III is the most common and up to 90% of isolates 
from infants with meningitis or from infants with late-onset disease caused by 
serotype III (Dele et al., 2001; Mavenyengwa et al., 2008; Florindo et al., 2011). In 
addition to serological methods for typing, recently developed multiplex PCR and 
DNA sequencing-based techniques allow the detection of capsular serotypes 
(Manning et al., 2003). 
 
2.4 Antibodies against GBS 
Antibodies to type-specific capsular polysaccharides (CPSs) of GBS in the serum of 
experimental animals and human neonates correlate with protection from GBS 
disease. The absence of antibody to GBS in infants is a risk factor for infections. Up 
to 90% of pregnant women may be deficient in type III CPS–specific antibody, which 
suggests a lack of priming by this antigen (Larsson et al., 2006). The precise 
concentration of CPS-specific antibody needed for protection of neonates may differ 
by serotype, bacterial inoculum, and possibly other factors; and the relative risk for 
colonization or invasive infection is related to the degree (inoculums size) of 
maternal colonization (Dele et al., 2001; Larsson et al., 2006). 
 
The GBS cell surface proteins α and Rib elicit protective immunity in animal models 
and have been suggested as potential antigens in a vaccine against human GBS 
neonatal infection. These proteins have been extensively characterized and belong 
to a family of streptococcal proteins with extremely repetitive sequence (Larsson et 
al., 2006).  Because antibodies to GBS provide protection against disease in animal 
models, there is an ongoing interest in vaccination as an approach for reducing the 
incidence of GBS colonization in healthy women (Lammler et al., 1995; Woods et al., 
2010).  
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2.5 Clinical manifestation 
2.5.1 GBS infections in newborns 
Group B Streptococcus is an important agent of serious neonatal infections     
(Figure 3). The most important risk factor for the development of invasive neonatal 
disease is the colonization of the maternal urogenital or gastrointestinal tract with 
GBS (Larsoon et al., 2006). In fact, about 1% of children born to mothers infected 
with GBS are prone to developing severe neonatal diseases such as neonatal 
sepsis, pneumonia, and meningitis (Rosetti et al., 1997; Mandell et al., 2010).  
 
The presenting signs of early-onset-disease in GBS infections include poor feeding, 
lethargy, raised temperature, granting respiration, hypotension, etc. In Late-onset-
Disease, some signs of EOD generally occur but in association with fever (to ≥380C). 
Bone and joints infections are other clinical forms of LOD. Newborn infections such 
as conjunctivitis, cellulitis, otitis media, and endocarditis can also be due to GBS 
(Mandell et al., 2010). Studies done elsewhere show that 25 - 50% of survivors of 
GBS meningitis, whether early- or late - onset, have permanent neurologic sequelae 
such as deafness, loss of hearing, mental retardation, etc. (Schrag et al., 2002; 
Mandell et al., 2010).  
                           
 
Figure 3: Neonate infected with GBS. Observe the Greenish liver visible through the abdomen (Larsoon et al., 
2006). 
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2.5.2 GBS infections in adults  
Group B Streptococcus is an important cause of illness in pregnant and non-
pregnant adults (female and male). Infection with GBS is commonly asymptomatic, 
this means GBS colonization does not result in symptoms and is not harmful (Faye-
Kette et al., 1991; Narayanan et al., 2006; CDC, 2010; Gray et al., 2011). However, 
colonization with GBS in pregnant women has been associated with adverse 
outcomes of the pregnancy, and hence the need for review of policy on screening 
and intrapartum eradication of GBS in the recto-vaginal tract. Invasive GBS infection 
causes substantial morbidity and mortality among the elderly people (+65 years old) 
and adults with underlying conditions, such as diabetes mellitus, liver disease, renal 
failure, neurologic impairment, cardiovascular disease, pulmonary disease, urologic 
disease, malignancy, cirrhosis, and immuno-compromised patients with alcoholism, 
including HIV-AIDS patients (Farley et al., 2001; Slaven et al., 2007; Mandell et al., 
2010; Gray et al., 2011).  
 
Most adult GBS infections occur in association with one of several expressions of 
infections; including primary bacteremia, meningitis, infection in female genital tract, 
and a variety of clinical manifestation, most common of these are endometritis and 
wound infection both associated with cesarean section; and pneumonia, and also 
skin and soft tissue infections, which includes foot ulcers, abscesses and cellulitis 
associated with foreign bodies (Manning et al., 2003; Gibbs et al., 2004; Murayama 
et al., 2009, Mandell et al., 2010). 
 
2.5.3 Spectrum of systemic infections caused by GBS 
2.5.3.1 Bacteremia  
Bacteremia is the presence of bacteria in the bloodstream.  This may occur through 
a wound or injection, or through surgical procedure. Bacteremia may cause no 
symptoms and resolve without treatment, or it may produce fever and other 
infections. If the immune system is damaged, septicemia may develop (Narayanan 
et al., 2006) 
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2.5.3.2 Sepsis 
Sepsis is a severe illness caused by overwhelming infection of the bloodstream by 
toxin producing bacteria. Neonatal GBS sepsis is characterized by clinical features 
such as fever, tachypnea and tachycardia. Common sites include the kidneys, liver, 
skin, and lung. Infection is confirmed by a positive blood culture (Humphreys et al., 
2000).  
 
2.5.3.3 Meningitis  
Meningitis is the inflammation of the meninges (membranes covering the brain or 
spinal cord), usually due to infections. Neonatal GBS meningitis occurs by route 
such as nosocomial infection. It often leads to permanent neurologic sequelae such 
as cerebral or cranial nerve palsy, epilepsy, mental retardation or hydrocephalus 
(Mandell et al., 2010). In adults, GBS meningitis is an important but uncommon 
manifestation of invasive GBS disease, and may account for up to 4% of all cases of 
bacterial meningitis. It is almost always associated with anatomical abnormalities 
contiguous with, or of, the central nervous system, usually as a result of 
neurosurgery. A small but significant proportion of survivors are left with neurologic 
sequelae such as permanent hearing loss (Farley et al., 2001).  
 
2.5.3.4 Pneumonia  
Pneumonia is an infection in one or both lungs. GBS pneumonia is rare and has few 
unique features. It generally occurs in older adults with diabetes and neurological 
impairment resulting from conditions such as cerebrovascular disease or dementia. 
In many cases aspiration is either documented or suspected. Pleural effusions are 
uncommon, and lung tissue necrosis is rare (Farley et al., 2001; Narayanan et al., 
2006).  
 
2.5.3.5 Skin and Soft tissue infections  
These are the most frequently reported clinical syndromes associated with invasive 
GBS. These infections most often present as cellulitis, decubitus ulcers, and infected 
foot ulcers. Many of these patients are diabetic (Bayer et al., 1976; Narayanan et al., 
2006).  GBS have occasionally been associated with wound and burn infections in 
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non-pregnant adults. Cases of necrotizing fasciitis and toxic shock–like syndrome 
associated with GBS have been reported (Tyrrell et al., 1996). 
 
2.5.3.6 Bone and joint infections  
GBS osteomyelitis most often occurs by contiguous spread or direct inoculation. The 
bones of the foot are frequently involved; this involvement is linked with vascular 
insufficiency and overlying ulcers and spreads from adjacent skin and soft-tissue 
infection. Vertebral osteomyelitis, usually in the lumbosacral area, is another 
common form of GBS osteoarticular infection (Farley et al., 2001; Narayanan et al., 
2006). 
 
2.5.3.7 Urinal tract infections 
Urinal tract infections (UTI) are more common in older individuals (mean age, 71 
years). Many patients with GBS urosepsis are nursing facility residents. In fact, 
between 5% and 23% of non-pregnant adults with invasive GBS disease are 
presented with a urinary tract infection. Most patients have significant predisposing 
conditions, such as diabetes mellitus, prostate disease, an indwelling urinary 
catheter, and anatomic abnormalities of the urinary tract. The presence of a 
neurogenic bladder has been associated with significantly increased risk for invasive 
GBS disease (Farley et al., 2001).  
 
Other conditions to be considered associated with GBS infections include otitis 
media, endocarditis, neurologic deficit, cellulitis, chorioamnionitis, diabetic foot, line 
infection, post-partum infections, septic arthritis, etc. (Farley et al., 2001; Narayanan 
et al., 2006). 
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2.6 Treatment approach in GBS infections 
There are several regimens for the treatment of infections with GBS. Antibiotics 
currently used for management of GBS include penicillin G, ampicillin, vancomycin, 
cefuroxime, cefotaxime, ceftriaxone, erythromycin, clindamycin, gentamicin, 
chloramphenicol, ciprofloxacin, and amoxicillin. However susceptibility testing must 
be done before any treatment is administered (Mandell et al., 2010). Duration of 
treatment depends on the clinical syndrome, risk of complications, response to 
therapy and the age of the patients (Simoes et al., 2004; Woods et al., 2010). 
 
2.6.1 Treatment of GBS infection in newborns 
Therapy depends on the infection focus. As presentation in neonates is non-specific, 
all neonates are treated almost the same once GBS infection is confirmed. ―Blind‖ 
antibiotic treatment is always recommended as soon as CSF and blood samples 
have been taken for Gram stain and culture (Mims et al., 2004). 
 
The first-line treatment is benzylpenicillin (Penicillin-G) or ampicillin, plus gentamicin. 
For children with penicillin allergy, a 2nd or 3rd generation cephalosporin (e.g. 
cefuroxime, cefotaxime or ceftriaxone) may be appropriate depending on the type of 
allergy, or vancomycin with or without gentamicin (British National Formulary (BNF), 
1993).  
 
Vancomycin is not suitable as monotherapy if meningitis is present. In the case of 
septic arthritis, joint must be aspirated and a formal washout in operating room is 
strongly recommended. Treatment course is 3 to 4 weeks.  An infectious-disease 
specialist should be consulted if polymicrobial infection is suspected (Narayanan et 
al., 2006; Woods et al., 2010).  
 
2.6.2 Treatment of GBS infection in pregnant women 
The most common infections are UTI, chorioamnionitis, sepsis, postpartum 
endometritis, and postpartum wound infection. The choice of antibiotic in pregnant 
women is influenced by the potential effects on the fetus. Likewise, the choice of 
antibiotic in postpartum infections is influenced by penetration into the breast milk 
(BNF, 1993).  
17 
 
Penicillin or ampicillin work synergistically with gentamicin as the 1st line treatment of 
chorioamnionitis and endometritis. For patients with penicillin allergy, a 2nd or 3rd 
generation cephalosporin may be appropriate depending on the type of allergy, also 
clindamycin, erythromycin or vancomycin plus gentamicin. Treatment course is 10 
days. Infection is often polymicrobial (Narayanan et al., 2006; Woods et al., 2010). 
 
2.6.3 Treatment of GBS infection in non-pregnant adults 
Benzylpenicillin or ampicillin is the first-line treatment for sepsis, cellulitis, septic 
arthritis and meningitis. A second or third generation cephalosporin or a macrolide, 
or clindamycin may be appropriate for patients with penicillin allergy, depending on 
the type of allergy. Gentamicin may be considered as adjunctive therapy in selected 
cases, but advice from an infectious-disease specialist must be sought, as the 
presentation is rare and management complicated.  The duration of treatment course 
is a minimum of 10 days for sepsis and cellulitis; and 14 to 21 days for meningitis; 
and 3 to 4 weeks for septic arthritis (BNF, 1993; Narayanan et al., 2006; Woods et 
al., 2010). 
 
In case of conjunctivitis, sinusitis, otitis media, endocarditis, soft-tissue infection, 
osteomyelitis and intra-abdominal infections, seek advices from an infectious-
disease specialist since these infections are often polymicrobial. As GBS infection 
occurs more commonly in older patients, hepatic and renal impairment must be 
taken into account when selecting dose of some drugs (Mandell et al., 2010; Woods 
et al., 2010).  
 
In case of urinary tract infections, the first-line treatment is amoxicillin or ampicillin. 
Penicillin or ampicillin with gentamicin is used for complicated infections such as 
pyelonephritis. Patients with penicillin allergy should be given trimethoprim, or 
nitrofurantoin, or vancomycin with or without gentamicin.  The duration of treatment 
course is 3 to 14 days (Narayanan et al., 2006).  
 
For pneumonia, 1st line treatment is benzylpenicillin or ampicillin. Patients with 
penicillin allergy, a 2nd or 3rd generation cephalosporin may be appropriate 
depending on the type of allergy. Vancomycin, linezolid, a macrolide, or a quinolone 
may also be used but antibiotic susceptibility testing must be done before any 
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treatment. Rifampicin or gentamicin may be considered as adjunctive therapy in 
selected cases (Narayanan et al., 2006; Woods et al., 2010). 
 
2.7 Antimicrobial agents in GBS 
Table 1 below lists some antibiotics used for GBS therapy infections, their 
antimicrobial spectra, origin and mode of action.   
 
Antibiotic Organism producer Active against Mode of action Effect 
Penicillin 
Erythromycin 
Clindamycin 
Ciprofloxacin 
Gentamicin 
Tetracycline 
Penicillium spp 
Streptomyces erythreus 
Streptomyces lincolnensis 
Streptomyces spp 
Micromonospora spp 
Streptomyces spp 
Gram + bacteria 
Common Gram + 
Gram
+ 
Gram+ 
Variety of Gram + 
Many Gram +  
Inhibit cell wall synthesis 
Interfere with protein synthesis 
Interfere with protein synthesis 
Block DNA replication 
Induce abnormal protein synth. 
Interfere with protein synthesis 
Bacteriocidal 
Bacteriocidal 
Bacteriostatic 
Bacteriocidal 
Bacteriocidal 
Bacteriostatic 
Source: Antibiotics used for Chemotherapy of GBS infections (Pelczar et al., 1993) 
 
2.7.1 Penicillin 
Penicillin is a beta-lactam antibiotic. Penicillin-G (Benzylpenicillin) is a powerful 
antibacterial agent widely used to inhibit the polymerization and attachment of new 
cell wall peptidoglycan synthesis by binding to the penicillin-binding proteins (PBPs). 
Penicillins diffuse well into body tissues and fluids; but penetration into the 
cerebrospinal fluid (CSF) is poor except when the meninges are inflamed (BNF, 
1993; Laurence et al., 1998).  
 
With its bactericidal effect, it is the first-line agent (drugs of choice) for the treatment 
of GBS infections (Laurence et al., 1998; CDC, 2010). An important feature is that so 
far there have been only very few cases or not at all substantiated reports of 
penicillin resistance (Mims et al., 2004; Murray et al., 2007).  
During the course of treatment, serious allergy to penicillins may occur in the form of 
an immediate (type1) hypersensitivity reaction, anaphylactic shock, rash, convulsion, 
diarrhea, platelet dysfunction, sodium overload. Penicillin-G can also produce 
neurotoxicity if given in high doses, particularly in patient with renal impairment. This 
toxicity is manifest as fits, unconsciousness and hallucinations (BNF, 1993; 
Laurence et al., 1998; Mims et al., 2004). 
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2.7.2 Ampicillin 
Ampicillin is a beta-lactam drug (broad spectrum penicillin) active against Gram 
positive and some Gram-negative organisms. Ampicillin is well excreted in the bile 
and urine. It is principally indicated for the treatment of exacerbations of chronic 
bronchitis, UTI, otitis media, sinusitis, invasive salmonella, and gonorrhea (Laurence 
et al., 1998; Mims et al., 2004).  
In GBS infections, no ampicillin resistance has been reported. Ampicillin can be 
given intravenously as an intrapartum antimicrobial prophylaxis in term women with 
culture evidence of recent vaginal or rectal GBS infection; starting 4hrs before 
delivery (CDC, 2010). 
 
2.7.3 Vancomycin 
Vancomycin is a very large molecule from the glycopeptide antibiotics family. It has 
bactericidal activity and is used mainly for the treatment of infections caused by 
Gram-positive cocci and Gram-positive rods that are resistant to beta-lactam drugs. 
It is also used as alternative for patients who are allergic to penicillin (Laurence et al., 
1998; Mims et al., 2004). 
 
Because it is a very large molecule, it has difficulty moving through the outer 
membrane to the peptidoglycan of Gram-negative cells; which makes them 
―naturally‖ resistant. Some organisms may acquire resistance to vancomycin; this is 
the case of vancomycin-resistant enterococci (VRE) (Laurence et al., 1998).  
 
A variety of resistance phenotypes have been described which can be differentiated 
by transferability (e. g. plasmid association), inducibility and extend of resistance. 
The genes associated with vancomycin resistances are vanA, vanB, and vanD which 
encode a ligase producing pentapeptides terminating in D-alanine-D-lactase (Mims 
et al., 2004).  
In GBS infections, no vancomycin resistance has been reported. 
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2.7.4 Erythromycin 
Erythromycin is the most important macrolide that exerts its action by binding to 50S 
subunits of bacterial ribosome; and inhibits (or blocks) protein synthesis of most 
Gram positive bacteria, because they accumulate the drug more efficiently than 
Gram negative bacteria (Laurence et al., 1998; Mims et al., 2004; Woods et al., 
2010).   
 
It is usually administered by the oral route, but can also be given intravenously (i/v). 
It is well distributed in the body and penetrates mammalian cells to reach intracellular 
organisms. The drug is concentrated in the liver and excreted in the bile. A small 
proportion of the dose is recoverable in the urine (Laurence et al., 1998; BNF, 1993). 
 
In GBS infections, erythromycin provides useful alternative therapy for penicillin-
allergic patients, but increase in the incidence of resistance has been observed. The 
erythromycin resistance mechanism is due to ribosomal modification conferred by a 
family of methyl-transferase enzyme (methylase) encoded by erm (erythromycin 
ribosomal methylation) genes.  Basically erm genes methylate 23S rRNA and induce 
ribosomal alteration which result in loss of binding and promote the so-called cross-
resistance to macrolides-lincosamides-streptogramin resistance ―MLS resistance‖ or 
MLSB (Back et al., 2012). The erythromycin resistance is also due to efflux pump 
mediated by the plasmid-encoded mef(A) gene that cause resistance to 14- and 15- 
membered macrolides (Weisblum et al., 1995).  
The resistance can either be inducible (iMLSB), where the methylase is in the 
presence of the inducer; or constitutive (cMLSB), where the methylase is produced 
constitutively. Erythromycin is a better inducer of resistance than lincosamides 
(Quiroga et al., 2008; Khan et al., 2011).  Strains resistant to erythromycin will also 
be resistant to lincomycin and clindamycin. Several erythromycin resistance 
determinants and genetic carrying elements in GBS strains have been reported such 
as ermB, ermA/TR, mef(A), mef(E), orf, intTn  (Arpin et al., 1999; De Azavedo et al., 
1999, De Mouy et al., 2001; Zeng et al., 2006). 
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2.7.5 Clindamycin 
Clindamycin is a bacterial protein synthesis inhibitor and represents the most 
important drug in the class of lincosamides. It binds to the 50S ribosomal subunit. Its 
antibacterial spectrum is similar to erythromycin (they both have bacteriostatic effect) 
and to penicillin (Laurence et al., 1998; Mims et al., 2004). Clindamycin is usually 
given orally, but can be administered intramuscularly (i/m) or intravenously (i/v). It 
penetrates well into bone, but not into CSF, even when the meninges are inflamed 
(BNF, 1993; Laurence et al., 1998). 
 
In GBS infections, clindamycin provide useful alternative therapy for penicillin-allergic 
patients, but an increase in the resistance to this alternative drug has also been 
observed. Clindamycin resistance in GBS is due to ribosomal translocation encoded 
by linB genes. In this case, the resistance mechanism is the methylation of the 23S 
binding site. If this occurs then the bacteria are resistant to both macrolides and 
lincosamides (Heelan et al., 2004).  As clindamycin is a less potent inducer of 23S 
rRNA methylase as mentioned in MLS, erythromycin-resistant strains may appear 
susceptible to clindamycin in vitro. However, resistance will be manifest in vivo 
(Mims et al., 2004). 
 
2.7.6 Gentamicin 
Gentamicin is the most important antibiotic of the aminoglycosides family widely 
used for the treatment of serious infections. With the bacteriocidal effect, it is active 
against many Gram-negative organisms and some Gram-positive (Laurence et al., 
1998; Tazi et al., 2012). 
Generally, gentamycin acts by binding to specific proteins in the 30S ribosome 
subunit, where it interferes with the binding of formylmethionyl-transfer RNA thereby 
preventing the formation of initiation complexes from which protein synthesis 
proceeds (Fluegge et al., 2004; Mims et al., 2004). It is not active against 
streptococci when used alone, but it acts in synergy with the beta-lactam agents 
(Laurence et al., 1998; Fluegge et al., 2004). Higher doses are occasionally 
indicated for serious infections, especially in the neonate or compromised host. A 
lower dose in association with Benzylpenicillin is sufficient for endocarditis due to 
oral and gut streptococci (Liddy et al., 2002). 
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Production of aminoglycoside-modifying enzymes is the principal cause of resistance 
to aminoglycosides. The genes for these enzymes are often plasmid-mediated, 
located on transposons, and transferable from one bacterial species to another (Tazi 
et al., 2012). Resistance to aminoglycoside antibiotics may occur by alteration of the 
30S ribosomal target protein, but also through alterations in cell wall permeability or 
in the energy dependent transport across the cytoplasmic membrane (Mims et al., 
2004). 
 
2.7.7 Tetracycline 
Tetracyclines are a family of large cyclic structures that have several sites for 
possible chemical substitutions. They are bacteriostatic and inhibit protein synthesis 
by binding to the small ribosomal subunit (30S ribosome) in a manner that prevents 
aminoacyl-tRNA from entering the acceptor sites on the bacterial ribosome; their 
selective action is due to higher uptake by bacterial than human cell (Laurence et al., 
1998; Mims et al., 2004).  
Generally, tetracycline resistance is due to a decrease in the levels of drug 
accumulation; and in most cases it is the plasmid encoded and inducible. The 
widespread use of this drug in human and also to their use as growth promoters in 
animal feed is one of the common causes of resistance (Mims et al., 2004).  
 
In GBS, tetracycline resistance is common; and genes are often found on the same 
mobile unit as erythromycin resistance; carried on transposon and usually due to 
ribosomal protection encoded by genes tet(M) and tet(O) or less commonly to an 
efflux pump encoded by tet(K) (Betrui et al., 2003). 
 
2.7.8 Ciprofloxacin 
Fluoroquinolones have bactericidal effect. They bind and inhibit the activity of 
enzyme DNA gyrase and topoisomerase IV and prevent them from decatenating. 
Because of their safety and tolerability, they are commonly used as alternatives to 
beta-lactam antibiotics for treating a variety of infections (Mims et al., 2004).  
Ciprofloxacin is the 2nd generation of quinolones that is active against Gram-negative 
bacteria, also has moderate activity against Gram-positive bacteria. Uses for 
ciprofloxacin include infections of respiratory, urinary tracts, and of gastro-intestinal 
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system and septicemia caused by sensitive organisms (Laurence et al., 1998; Mims 
et al., 2004).  
 
Mutations at key sites in DNA gyrase or topoisomerase IV can decrease their biding 
affinity to quinolones, decreasing the drug’s effectiveness and create resistance (Wu 
et al, 2008). In GBS infections, the resistance is caused by mutation position in the 
quinolone resistance-determining regions (QRDRS) of the genes coding for type II 
topoisomerase enzymes, i.e. DNA gyrase (gyrA/gyrB) and topoisomerase IV 
(parC/parE)  (Wehbeh et al., 2005; Wu et al., 2008). 
 
2.7.9 Chloramphenicol 
Chloramphenicol is a relatively simple molecule containing a nitrobenzene nucleus, 
and prevents peptide bond synthesis, with a bacteriostatic result. It may be 
bactericidal against H. influenza, N. meningitis and S. pneumonia (Laurence et al., 
1998). 
It acts by binding on the 50S ribosome subunit, where it blocks the action of peptidyl-
transferase, thereby preventing peptide bond synthesis. It has been used in the 
treatment of bacterial meningitis since the drug achieves satisfactory concentration 
in the CSF. It is active against both Gram-positive bacteria and Gram-negative 
bacteria, but it is a potent and potentially toxic. Its toxicity renders it unsuitable for 
systemic use except in some circumstances (Laurence et al., 1998; Mims et al., 
2004). The most common mechanism of chloramphenicol resistance involves the 
inactivation of the drug by a plasmid mediated enzymatic, mechanism which is easily 
transferable to bacterial population, especially Gram-negative bacteria (Mims et al., 
2004).  
 
2.8 Multiplex Polymerase Chain Reaction in determining GBS resistance 
Multiplex Polymerase Chain Reaction (PCR) is a variant of PCR which enable 
simultaneous amplification of many targets of interest in one reaction by using more 
than one pair of primers. It consists of multiple primer sets within a single PCR 
mixture to produce amplicons of varying sizes that are specific to different DNA 
sequences (Chamberlain et al., 1988).  
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Multiplex PCR is becoming a rapid and convenient screening assay in both clinical 
and research laboratories. This method has been applied in many areas of DNA 
testing, including analyses of deletions, mutations, and polymorphisms, or 
quantitative assays and reverse transcription PCR (Henegariu et al., 1997). For a 
successful multiplex PCR assay, strategic planning and multiple attempts to optimize 
reaction conditions are required. The relative concentration of the primers, 
concentration of the PCR buffer, balance between magnesium chloride and 
deoxynucleotide concentrations, cycling temperatures, and amount of template DNA 
and Taq DNA polymerase are important (Markoulatos et al., 2002). 
 
In GBS infections, multiplex PCR has been used to detect antibiotic resistant genes. 
In a study performed in four countries Australia, New Zealand, South Korea and 
China, multiplex PCR methods detected 7 genes encoding antibiotics resistance 
against GBS, erm(A/TR), erm(B), mef(A), tet(M), tet(O), aphA-3, and aad-6; and 
antibiotic related gene (int-Tn) and mreA, encoding flavokinase, were also present in 
all GBS isolates. This study has shown the higher rate of phenotypic resistance to 
erythromycin, clindamycin and tetracycline which varied with geographic area (Zeng 
et al., 2006). 
 
Gygax et al., in 2007 used a multiplex PCR assay to detect erythromycin and 
clindamycin resistance genes, ermB, ermTR, and mefA/E, in GBS clinical isolates 
and in DNA extracted from the corresponding cervico-vaginal-rectal (CVR) swabs. 
The results were compared to the standard erythromycin / clindamycin double disk 
diffusion assay of 46 isolates. The PCR could accurately detect resistance genes 
and predict the resistance phenotype from purified GBS isolates. 
 
Recently in Poland, in 2012, standardization of multiplex PCR with the use of seven 
primer pairs was performed on 81 bacterial strains representing different GBS 
isolates and other Gram-positive cocci. As a result, seven genes important for 
screening of GBS infection were detected: cfb gene encoding the CAMP factor 
presented in every GBS; the cps operon genes such as cps1aH, cps1a/2/3IJ, and 
cps5O specific for capsular polysaccharide types Ia, III, and V, respectively were 
also detected; the macrolide resistance genes ermB and mefA/E were detected; and 
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finally the gbs2018 S10 region specific for ST17 hyper-virulent clone were also 
detected (Gosiewski et al., 2012).  
 
2.9 Prevention of GBS infections  
Pregnant women with the following conditions are at higher risk of having a baby 
with GBS disease: previous baby with GBS disease, urinary tract infection due to 
GBS, fever during labor, prolonged or difficult labor, rupture of membranes before 37 
weeks of pregnancy, and rupture of membrane 18 hours before delivery (Murray et 
al., 2007).  
 
The Centre for Disease Control and Prevention (CDC) recommends the use of either 
risk assessment or screening for GBS colonization in pregnant women to identify 
candidates for intrapartum prophylaxis. Risk assessment is performed at the onset of 
labor and conditions sus-mentioned and considered indicative of the need for 
prophylaxis. The current screening approach to prevention of GBS infections in 
pregnancy has become standard. This approach requires intra-partum antimicrobial 
prophylaxis in term women with culture evidence of recent vaginal or rectal GBS 
infection. The affected pregnant women can be given intravenous antibiotics during 
labor; starting 4h before delivery. These recommendations are based on the fact that 
administration of antimicrobial agents during labor to women at risk of transmitting 
GBS to their newborns could prevent invasive disease in the first week of life 
(Bergseng et al., 2007; Murray et al., 2007; CDC, 2010).  
 
2.10 Vaccines against GBS Disease 
GBS vaccines have been recognized as a powerful tool for reducing maternal 
colonization and preventing transmission to neonates, but  no licensed vaccine is yet 
available (CDC, 2010). Sufficient amounts of GBS capsular polysaccharide type-
specific serum IgG in mothers have been shown to protect against invasive disease 
in their infants. Phase I and II clinical trials among healthy non-pregnant adults of 
monovalent polysaccharide-protein conjugate vaccines of GBS have shown these 
vaccines to be well tolerated and immunogenic (Baker et al., 1988; CDC, 2010). 
 
Vaccine development was once promising, but shifting serotypes of GBS responsible 
for clinical disease have limited this approach. Other factors that have made this 
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approach less attractive include problems related to access to vaccination by women 
of childbearing age and the emotion and possible litigation associated with 
vaccination during pregnancy (Bergseng et al., 2007; Woods et al., 2010).    
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CHAPTER III 
MATERIALS AND METHODS 
3.1 Study area   
This study was conducted from February 2012 to December 2012 at Dr. George 
Mukhari Academic Hospital, formerly Ga-Rankuwa Hospital, in Pretoria (Tshwane); 
South Africa. This is an academic Hospital associated with the University of 
Limpopo, MEDUNSA Campus (Medical University of Southern Africa), located about 
37 km north of Pretoria in Gauteng Province. It lies at an altitude of about 1.350m 
(4.500 ft) above the sea level; in a Longitude of 25º37’14’’ S and a Latitude of 
28º1’1’’ E. 
 
3.2 Ethical Consideration 
The study was approved by the Medical Research and Ethics Committee of South 
Africa (MREC/P/02/2011: IR) and Directorate for Health and Social Affairs 
(MEDUNSA) and the College of Agriculture and Environmental health Sciences, 
University of South Africa (CAES – UNISA). 
 
3.3 Experimental design  
This was a qualitative and prospective study. The study population constituted 
pregnant women and newborn babies. Samples were obtained from patients 
attending the antenatal clinic (ANC) from 16 weeks of gestation to form a cohort 
group.  
 
Specimens were collected from the mothers (high vaginal swab, lower vaginal swab 
and rectal swab), and from babies (ear swab, umbilical swab and cord blood) and 
transported to the laboratory for culture within 4 hours of collection. Processing of 
samples followed the standard operating procedures (SOPs) developed for the 
study. 
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3.4 Sampling 
3.4.1 Sample size 
Based on an estimation of 30 pregnant women seen at the antenatal clinic (ANC) per 
day, the estimated population was 20 000 women over a 2 year period. At an 
expected frequency of 10%, confidence level of 95% and a margin of error of 5% 
sample size was estimated at about 300. Due to the challenges of loss to follow up 
which are expected with a cohort, the sample size was increased to 500 to 
accommodate for anticipated lost follow-up and home deliveries. However only 413 
samples were collected from pregnant women and 39 samples were collected from 
babies.  MS Excel and Epi info was used to capture the data and analysis was 
partially by Epi info and PSSP.  
 
3.4.2 Sample Collection 
Random convenience sampling method was used. All pregnant women seen at the 
ANC were informed about the nature and implication of the study and those who 
agreed (volunteered) to participate were requested to sign a consent form (Appendix 
A) before they were recruited. Recruitment continued until sample size of 413 was 
reached. This then formed the cohort that was followed-up to delivery and post-
delivery including their babies.  
A questionnaire (Appendix B) was also used to gather demographic, obstetric and 
current pregnancy history data from all pregnant women recruited. At delivery the 
baby’s details were also recorded (Appendix C). 
 
Gynecologist, obstetrician, pediatrician and the research nurses collected the 
specimens. The procedure for the collection was explained to the patients before the 
specimens were taken (Figure4). Samples were taken aseptically. High vaginal 
swabs (HVS), low vaginal swabs (LVS) and rectal swabs (RS) were collected from 
pregnant women (figure 4)  attending ANC at DGMH, at the gestational period of 16 
– 38 weeks, who signed informed consent, and received no antibiotics for at least 
two weeks prior to sample collection. At delivery repeat samples were collected from 
pregnant women and umbilical swabs (US) and ear swabs (ES) were collected from 
their newborn babies too.  
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Inclusion criteria: 
Pregnant woman attending ANC at DGMAH from 16 weeks gestation, aged of 18 
years and above, and babies born from identified positive women 
 
Exclusion criteria: 
Pregnant women who were not willing or unable to give consent; those who were on 
antibiotic treatment 2 weeks prior to recruitment 
 
                
Figure 4: Site for collection of recto-vaginal specimen for GBS isolation  
           (Adapted from BD diagnostics www.geneohm.com; Musa et al. 2012).                                                                                                                                                                                  
3.4.3 Culture of specimens 
Swabs were placed into a Amie’s transport medium, (Rochelle Chemicals & Lab 
equipment, SA), properly labeled and put into a cooler box containing ice packs, and 
transported to the laboratory of Microbiological Pathology department, University of 
Limpopo, Medunsa campus within 2 - 4 hours of collection. Specimens collected 
from mothers and babies were cultured on selective medium, 5% blood of Columbia 
colistin and nalidixic acid (CNA) agar (DMP – NHLS, SA); and all incubated for 24 - 
48hours in a 5% CO2 atmosphere at 37ºC. Growth was quantified as abundant or 
+++ (more than 21 colonies per plates), moderate or ++ (11 - 20 colonies) and 
sparse or + (1 - 10 colonies). The negative swabs from CNA were then inoculated in 
enriched selective GBS broth, Todd-Hewitt broth (DMP-NHLS, SA), with the same 
antibiotics concentration as in CNA (15 mg/l nalidixic acid and 8 mg/l gentamicin). 
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Growth was quantified as heavy, moderate or scanty considering the growth from the 
main inoculum and the streaks.  
 
Todd Hewitt broth was incubated overnight at 37ºC sub-cultured onto blood agar and 
plates read after 24 – 48 hours of incubation in a CO2 enriched environment at 37ºC. 
Isolates with colony morphological description similar to GBS were further identified 
for confirmation.  
 
3.4.4 Confirmatory tests for identification of GBS 
Isolates were confirmed as GBS by using the following methods: morphology of 
bacteria, hemolytic activity, Catalase test, microscopy (Gram’s stain), bile esculin, 
and CAMP reaction following by latex agglutination test (Streptex – Slidex ® Strepto 
Plus – BioMérieux – France, Randburg – SA) for antigen detection. 
 
For validation of the tests, S. agalactiae ATCC 12403 was used as positive control 
as previously described in the literature (Kimura et al., 2008);  
 
3.4.4.1 Hemolytic activity 
Any blood agar plate showing a complete destruction of red blood cells leaving a 
clear zone (β-hemolysis) were scored as a positive reaction indicating GBS growth. 
Some isolates were non-hemolytic but positive for GBS. 
 
3.4.4.2 Gram stain 
The objective was to differentiate bacteria in two groups depending on their abilities 
to retain a particular stain in the cell wall. After the process of staining of the fixed 
smear containing organism with a primary stain (crystal violet) for 1 minute; then the 
application of Gram’s iodine (Mordant) for 1 minute; then the washing of the stained 
slide for 30 seconds with a decolorizing agent (95% ethanol); and finally the 
application of counterstain (Safranin) for 3 minutes. Gram-positive bacteria stained 
purple and Gram-negative pink. It should be noted that GBS is a gram positive 
coccus.  
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3.4.4.3 Catalase test 
The objective of this test was to determine the presence of catalase enzyme in 
isolate using hydrogen peroxide (H202) tests. Few drop of H202 (3%) were placed on 
a clean slide, using sterile applicator sticks, isolates were mixed with H202. The 
vigorous gas bubbles production indicated positive reaction. GBS is catalase 
negative. 
 
3.4.4.4 Bile Esculin test 
The objective of this test was to distinguish GBS from group D streptococci and 
Enterococci; bacteria able to hydrolyse esculin in the presence of bile. Bile esculin 
medium contains esculin and peptone for nutrition and bile to inhibit Gram-positive 
bacteria other than Group D streptococci and enterococci. Ferric citrate is added as 
a colour indicator. Organisms that split the esculin molecules and use the liberated 
glucose to supply energy needs release esculetin into the medium. The free 
esculetin reacts with ferric citrate in the medium to form a phenolic iron complex, 
which turns the agar slants dark brown to black. An agar slant that is more than half 
darkened after no more than 48 hours’ incubation is bile-esculin positive. If less than 
half the slant has darkened, the result is negative. It should be noted that GBS is bile 
negative. Enterococcus faecalis ATCC 29212 was used as positive control. 
 
3.4.4.5 Latex agglutination test 
Lancefield group B antigen detection was performed according to the manufacturer’s 
instruction. Latex agglutination test is a rapid test detecting protein antigen. Colonies 
were identified as GBS using a commercial latex agglutination test or streptex 
(Slide® Strepto Plus - BioMérieux® – France; Randburg – SA). 
 
3.4.4.6 CAMP reaction (Christie Atkins and Munch-Petersen) 
The objective of this test was to separate GBS from other β-hemolytic species. GBS 
produce a peptide, the CAMP substance, which acts in concert with the β-
haemolysis produced by some strains of Staphylococcus aureus, resulting in an 
increased haemolytic effect (Figure 5). Sheep blood agar plate was taken. Using a 
sterile loop, a single line of S. aureus was streaked on agar, and another line of the 
isolate was streaked as a ―T‖ without allowing the horizontal lines to touch the 
vertical line. And plate was incubated at 37ºC in an inverted position. Upon 
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successful completion of CAMP reaction, we noted a formation of an arrowhead 
pattern of hemolysis at the intersection of the two isolates. Staphylococcus aureus 
ATCC 29213 was used for the test. 
 
 
                 
      Figure 5: CAMP test for the identification of S. agalactiae (Adapted from ASM Microlibrary.org)  
      (A) Streptococcus agalactiae (group B) shows a positive CAMP reaction.  
      (B) Streptococcus pyogenes (group A) shows a negative reaction 
      (C) Staphylococcus aureus  
 
3.4.5 Storage of isolates 
All isolates that were confirmed to be GBS were stored at -80oC in cryovials 
(microbank) containing cryo-preservative fluid for future use. A data sheet and work 
sheet were developed (Appendix D and E). 
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3.5 Antibiotic Susceptibility Testing 
3.5.1 Phenotypic testing 
To determine the phenotypic resistance, the susceptibility testing was done 
qualitatively using Disk Diffusion (Kirby-Bauer) method and Double-disk Diffusion (D-
test) as previously described (Quiroga et al., 2007; Khan et al., 2011); and 
quantitatively using the Epsilometer tests (E-Tests) as previously described 
(Manning et al., 2001). Agar based susceptibility testing methods (Disk Diffusion and 
E-Tests) are widely used due to their simplicity, reproducibility, and lack of 
requirement for specialized equipment comparatively to the automated system or 
Vitek (Tang et al., 2004).  
 
3.5.1.1 The Disc Diffusion Test (Kirby-Bauer method)  
This is a standardized qualitative testing method used to measure the effectiveness 
of a variety of antibiotics on specific bacteria. A minimum of two pure small colonies 
were selected from an overnight positive GBS plate, suspended into normal saline 
and adjusted until the turbidity was equivalent to the 0.5McFarland standard 
(Rochelle Chemicals). The sterile swab was dipped into the suspension and used to 
inoculate onto Mueller-Hinton agar (MHA) supplemented with 5% sheep blood. By 
using the dispenser or sterile forceps, the antibiotic impregnated paper disks were 
placed onto agar; and incubated at 37ºC for 20-24h in 5% CO2 environment.  The 
plates were read the following day; the zones of growth inhibition were measured to 
the nearest whole millimeter using a sliding caliper or ruler. Each isolate was 
classified as susceptible, intermediate or resistant to each antibiotic tested.  
 
The susceptibility to ampicillin (AMP) (10μg), vancomycin (VA) (30μg), ciprofloxacin 
(CIP) (5μg), high level gentamicin (CN) (120μg), chloramphenicol (C) (30μg), and 
tetracycline (TE) (30μg) was tested (Oxoid, Davies-Diagnostics, South Africa).  
 
Results were interpreted according to Clinical Laboratory Standard Institute (CLSI) 
guidelines 2012, breakpoints criteria M100-S22, as indicated in Table II. 
 
 
34 
 
3.5.1.2 The Double Disk Diffusion Test (D-test) 
This qualitative method was used for phenotypic characterization and detection of 
inducible clindamycin resistance.  
 
Erythromycin (15µg) and clindamycin (2µg) disks (Oxoid, Davie’s – Diagnostics, SA) 
were placed 12 mm apart, edge to edge (CLSI, 2012) on Mueller-Hinton agar 
supplemented with 5% sheep blood agar (DMP – NHLS, SA) which were inoculated 
with a 0.5 McFarland suspension of the organism. The plates were incubated for 20 
– 24 h at 37°C in 5% CO2 atmosphere. 
 
Blunting was defined as growth within the clindamycin zone of inhibition proximal to 
the erythromycin disk, indicating MLSB-inducible methylation. Resistance to both 
erythromycin and clindamycin indicated MLSB-constitutive methylation. Resistance to 
erythromycin but susceptibility to clindamycin without blunting indicated an efflux 
mechanism (M phenotype). And finally resistance to clindamycin but susceptible to 
erythromycin was referred as L phenotype as previously described (Desjardins et al., 
2004; Quiroga et al., 2007; Khan et al., 2011). 
 
3.5.1.3 The Epsilometer test (E-Test)  
This quantitative method was done following the manufacturer’s procedure. Briefly, a 
commercially available paper strip (AB Biodisk, Solna – Sweden, Davie’s  
Diagnostics – South Africa), which is soaked with antibiotic gradients (antibiotic 
concentration decreased from one point of the paper strip to the other) was placed 
onto Mueller-Hinton agar supplemented with 5% sheep blood (DMP – NHLS, SA) 
following bacterial inoculation (0.5 McFarland of bacterial suspension). The plates 
were incubated at 37ºC for 24 h, in a 5% CO2 enriched environment at 37ºC. MICs 
were read as the lowest concentration of antibiotic that inhibit the bacterial growth.  
 
Susceptibility to penicillin, erythromycin and clindamycin were tested. And results 
were interpreted according to CLSI guidelines 2012. 
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Table II: Interpretation of size of zone of inhibition, Breakpoints criteria (CLSI, 2012: M100-
S22) 
Antibiotic Disc 
Concentration 
Diameters breakpoints (mm) 
Susceptible (S) Intermediate 
(I) 
Resistant (R) 
E – test     
- Penicillin 10units ≤ 0.12 - - 
- Erythromycin 15µg ≤ 0.25  0.5 ≥1 
- Clindamycin  2µg ≤ 0.25  0.5 ≥1 
Disc Diffusion     
- Penicillin 10U ≥ 24 - - 
- Ampicillin 10µg ≥ 24 - - 
- Vancomycin 30µg ≥ 17 - - 
- Erythromycin 15µg ≥ 21 16-20 ≤15 
- Clindamycin 2µg ≥ 19 16-18 ≤15 
- Chloramphenicol 30µg ≥ 21 18-20 ≤17 
- Tetracycline 30µg ≥ 23 19-22 ≤18 
- Gentamicin 120µg ≥ 15 13-14 ≤12 
- Ciprofloxacin 10µg ≥ 21 16-20 ≤15 
 
Source: OXOID, 2012; CLSI, 2012. Performance standard for antimicrobial susceptibility testing, 
M100-S22, Table 2H-1, Wayne, Pa: CLSI recommends disk diffusion (M-2) or broth micro-dilution 
testing (M-7) for susceptibility testing of GBS.  
 
Quality Control  
The Clinical and Laboratory Standards Institute (CLSI) antimicrobial susceptibility 
testing standards were used to derive a correlation between the zone of inhibition 
and the Minimum Inhibitory Concentration (MIC) of the test organism; and results 
were interpreted according to CLSI guidelines for streptococcus spp, β-hemolytic 
group 2012 breakpoint for disk diffusion. 
A penicillin-susceptible S. agalactiae ATTC 12403 and S. pneumoniae ATCC 49619 
were used as positive quality control strains for measurement of the exact MICs as 
previously described (Kimura et al., 2008; CLSI, 2012).  
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3.5.2 Genotypic Identification  
During the study, molecular techniques were used for the identification of genotypic 
resistance among all the erythromycin and clindamycin resistant isolates for the 
detection of resistant genes.  
 
3.5.2.1 DNA extraction 
DNA extraction was done using the Zymo Research–DNA Mini-Kit (Zymo-Research–
USA; Inqaba Biotec – SA) and following the manufacturer instructions (Appendix G).  
 
Briefly, 200 µl of sterile water was added into 1.5ml micro-centrifuge tube. Bacterial 
cells (from overnight growth) were suspended into the above water and 100 mg (wet 
weight/colonies) of the suspension was added into ZR Bashing-Bead Lysis tubes 
(provided by supplier). 750 µl of lysis solution was added to the tube (ZR Bashing-
Bead Lysis tubes) and secured in a bead beater (Disruptor Genie) and processed at 
maximum speed for 5 minutes.  
The ZR Bashing-Bead Lysis Tubes were centrifuged at 10,000 x g (10,000 RPM) for 
1 minute. Up to 400µl of supernatant was transferred to a Zymo-Spin IV Spin Filter 
(orange top) in a collection tube and centrifuged at 7,000 x g (7,000 RPM) for 1 
minute. 1200 µl of Bacterial DNA Binding buffer was added to the filtrate in the 
collection tube from step above. 800 µl of the mixture from step above was 
transferred to a Zymo-Spin IIC column in a collection tube and centrifuged at 10,000 
x g (10,000 RPM)  for 1 minute; the flow from the collection tube was discarded (this 
step was repeated twice). 200 µl DNA Pre-Wash Buffer was added to the Zymo-spin 
IIC column in a new collection tube and centrifuged at 10,000 RPM (10,000 x g) for 1 
minute. 500 µl Bacterial DNA Wash Buffer was added to the Zymo-spin IIC column 
and centrifuged at 10,000 RPM (10,000 x g) for 1 minute. The Zymo-Spin IIC column 
was transferred to a clean 1.5 ml microcentrifuge tube.  Finally 100 µl DNA Elution 
Buffer was added directly to the column matrix and centrifuged at 10.000 RPM 
(10,000 x g) for 30 seconds to elute the DNA.  
A total of 5 µl of the Ultra-pure DNA was used in the experiments 
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3.5.2.2 Primer sets used for Multiplex PCR 
To ensure easy detection of fragments, multiplex PCR was designed. The primers 
were separated according to their fragment sizes, to make reading of the band sizes 
much easier. Three genes for macrolide resistance, ermB, ermTR, mefA and one 
gene for clindamycin resistance linB were identified with sets of specific primers as 
previously described (Sutcliffe et al., 1999; De Azavero et al., 2001; Desjardins et al., 
2004; Gygax et al., 2007).  
Table III below shows specific primers (synthesis at Inqaba Biotec – SA) used for the 
detection of resistance genes in GBS, their gene targets and their product size. 
 
Table III: Specific primers used for the detection of resistance genes in GBS 
Gene 
targets 
Primers 
name 
Primers sequence (5’- 3’) Products 
size: bp 
References 
ermB ermB1 
ermB2 
5’_-GAA AAG GTA CTC AAC CAA ATA-3’_ (F) 
5’_-AGT AAC GGT ACT TAA ATT GTT TAC-3’_ (R) 
640 Sutcliffe et al., 1999; 
De Azavedo et al., 2001 
ermTR ermTR1 
ermTR2 
5’_-GAA GTT TAG CTT TCC TAA-3’_ (F) 
5’_-GCT TCA GCA CCT GTC TTA ATT GAT-3’_ (R) 
400 Desjardins et al., 2004 
Gygax et al., 2007 
mefA  mefA1 
mefA2 
5’_-AGT ATC ATT AAT CAC TAG TGC-3’_ (F) 
5’_-TTC TTC TGG TAC TAA AAG TGG-3’_ (R)  
348 Sutcliffe et al., 1999; 
Gygax et al., 2006 
linB linB1 
linB2 
5’_-CCT ACC TAT TGT TTG TGG AA-3’_ (F)  
5’_-ATA ACG TTA CTC TCC TAT TC-3’_ (R) 
944 Gygax et al., 2006; 
Gygax et al., 2007 
 
3.5.2.3 Amplification of erythromycin and clindamycin genes 
An SOP was developed and different genes of resistance to GBS were detected by 
using Multiplex PCR and conditions as previously described (Gygax et al., 2007).  
 
A 50µl PCR  reaction contained 2.5 mM Tris-HCl pH 8.6, 2.5mM KCl, 2.5 mM MgCl2,    
5 mM dNTP, 0.5U Taq DNA polymerase (Thermo Scientific – Phusion Flash High-
Fidelity PCR Master Mix), PCR water, and 1 µM primers pairs  (Inqaba - Biotec - 
SA). A total of 5µl template DNA was used in the PCR.  
 
The cycling conditions on a My Cycler TM thermal cycler (BioRad) consisted of  a 
single cycle of 95°C for 3 minute followed by 35 cycles of denaturation at 95°C for 1 
minute, annealing at 57°C for 1 minute and extension at 72°C for 1 minute. A final 
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extension step of 72°C for 5 minutes was followed by a hold at 4°C (Desjardins et al., 
2004). 
3.5.2.4 Detection of amplified products 
Electrophoresis on 1% agarose gels in 40 mM Tris acetate–2 mM EDTA buffer was 
used to distinguish PCR products (PCRP) as previously described (De Azavedo et 
al., 2001). The different genes of resistance were analyzed based on presence or 
absence of bands in the agarose gel 
A culture of GBS ATTC 49447 was used as negative control. 
 
3.6 Results analysis 
All data were captured using Microsoft Excel 2010. The different variants were 
analyzed based on the parameter considered; and finally IBM-SPSS Software 
Version 21 was partially used to analyze data. 
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CHAPTER IV 
RESULTS 
 
Over a period of 11- months; February to December 2012, a total of 413 adult black 
pregnant women at Dr. George Mukhari Academic Hospital were recruited; and at 
delivery 39 samples were collected from the babies born to colonized mothers. This 
study population comprised only of the pregnant women who agreed to participate in 
the study and who met the selection criteria as listed in point 2.3.2. 
 
4.1 GBS culture 
Of the 413 pregnant women recruited, 128 (30.9%) were colonized with GBS and of 
39 babies recruited none of them (0%) was colonized with GBS (see the Table IV 
below)  
Table IV:  GBS colonization by site and by use of GBS selective media. 
Number of samples 
collected 
Mothers Babies 
413 39 
Number of positive GBS  
isolated 
CNA TH CNA TH 
RS LVS HVS All sites  
70 
ER US  
- 22 9 3 24 - 
58 - 
128 (30.9%) 0 
 
GBS negative 285 (69.1%) 39 (100%) 
 
 
Key: CNA : Colistin nalidixic acid agar   HVS : Higher vaginal swab   
TH : Todd-Hewitt broth   ES : Ear swab    
RS : Rectal swab    US : Umbilical swab   
LVS : Lower vaginal swab      
40 
 
The table IV shows that 128/413 (30.9%) pregnant women were GBS positive and 
285 (69%) were GBS negative. The difference between the GBS positive and the 
negative GBS was not statistically significant.  
 
From the 128 positive GBS isolated; 70 (54.6%) were recovered from Todd-Hewitt 
broth and 58 (45.3%) from CNA agar. The difference was no significant between 
positive GBS recorded from Todd-Hewitt broth and CNA agar. From CNA agar, 
rectal site was found to be the commonest site of the colonization; with an overall of 
22/58, following by LVS (9/58) and HVS (3/58) and finally 24/58 isolates were found 
in all sites at the same time. Thirty-nine samples were collected from the babies born 
to colonized mothers and none of them were GBS positives. Most of these babies 
were born by cesarean section. 
 
4.2 Study Participants 
4.2.1 Demographic Data  
The questionnaire was used to collect and record demographic data. The socio-
demographic characteristics of 413 pregnant women screened for GBS colonization 
against the positive women (n=128) at Dr. George Mukhari Hospital, Ga-Rankuwa in 
Pretoria (Feb 2012 - Dec 2012) is presented in tables Va, Vb, Vc and Vd below.   
 
Table Va: Age distribution of women recruited (n=413) in comparison to 
women colonized with GBS (n=128) 
Age in years 18 – 19 20 – 24 25 – 29 30 – 34 35 – 39 40 – 45 
Women recruited 
(%) 
12 (2.9) 75 (18.1) 110 (26.6) 95 (23.0) 81 (19.6) 30 (7.2) 
GBS Positive (%) 2 (1.5) 28 (21.8) 39 (30.4) 24 (18.7) 24 (18.7) 10 (7.8) 
 
Table Va shows the difference in age distribution between participants recruited and 
GBS positive women was not significant. The age range of participants was between 
18–44 years with the majority of the participants recruited 110/413 (26.6%) being 
between the ages of 25 – 29 years old and 30.4% of them being colonized with GBS. 
Of 95 (23%) women recruited were between 30 – 34 years old and 24 (18.7%) of 
them were GBS positive. Women of age range 18 – 19 years had the lowest rate of 
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GBS colonization (1.5%). During the recruitment time and processing, ten data were 
lost and one of them was GBS positive. 
 
Table Vb: Comparison of marital Status of women recruited (n=413) against 
women colonized with GBS (n=128) 
Marital status Single Married Divorced Widowed Co-habiting 
Women recruited (%) 209 (50.6) 98 (23.7) 03 (0.7) 02 (0.4) 89 (21.5) 
GBS Positive (%) 68 (53.1) 27 (21) 1 (0.7) 0 (0) 31 (24.2) 
 
Considering the marital status of the participants and GBS colonized pregnant 
women, the difference was not significant. The table Vb shows that almost half of the 
participants were single (50.6%); followed by 23.7% of participants who were 
married; 21.5% of participants were co-habiting; 3 (0.7%) and 2 (0.4%) participants 
were divorced and widowed, respectively. 
 
NB. The term ―Cohabiting‖ refers to the arrangements where two people who are 
not married live together in an intimate relationship, particularly an emotionally and/ 
or sexually intimate one, on a long-term or permanent basis. This is a common 
pattern among people for a number of reasons such as financial, housing, or seeing 
no need to marry (and some people don’t believe in marriage), etc.  
 
Table Vc: Educational level of women recruited (n=413) in relation to women 
colonized with GBS (n=128) 
Educational level Below-matric Matric Tertiary 
Women recruited (%) 107 (25.9) 229 (55.4) 67 (16.2) 
GBS Positive (%) 36 (28.1) 76 (59.3) 15 (11.7) 
 
Considering the educational level, the table Vc shows that approximately 55.4% 
(229/413) of participants recruited reached the matric level and 59.3% (76/128) of 
them tested positive for GBS; while 107/413 (25.9%) were below matric and 36/128 
(28.1%) were GBS positive; and 67/413(16.2%) with tertiary level education of which 
15 (11.7%) were GBS positive.  
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Table Vd: Employment status of women recruited (n=413) in comparison to 
GBS colonization (n=128) 
Occupational status Employed Unemployed Skilled Semi-skilled Unskilled 
Women recruited (%) 148 (35.8) 255 (61.7) 41 (9.9) 67 (16.2) 18 (4.3) 
GBS Positive (%) 51 (39.8) 76 (59.3) 10 (7.8) 22 (17.1) 3 (2.3) 
 
Out of 413 participants recruited, 225 (61.7%) were unemployed and 59.3% of them 
were colonized with GBS and 35.8% of participants employed where 39.8% of them 
tested positive for GBS. Forty-one participants (9.9%) were skilled, 67 (16.2%) were 
semi-skilled, 18 (4.3%) were unskilled. 
 
4.2.2 Data on obstetric and history of current pregnancy 
The obstetric and history of current pregnancy were recorded. Of the 128 colonized 
pregnant women, 22 (25%) reported previous history of miscarriage; 12 (9.3%) 
history of stillbirth and 62 (48.4%) had given normal vaginal delivery in which 25 
(12.1%) had given birth by caesarean section (C/S) and 4 women (1.9%) had 
terminated their pregnancy due to several reasons. 
Of the 128 colonized women, 56 (43.7%) complained of flu like illness during early 
pregnancy; 6 (4.6%) had trauma in pregnancy; and 22 (17.1%) had vaginal 
discharge requiring treatment.  
From 128 GBS positive women, a total of 52 (40.6%) were HIV positive and 72 
(56.2%) were HIV negative.  
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4.3 Antimicrobial susceptibility  
Purification of isolates was done before susceptibility testing. The susceptibility 
pattern was performed on 128 positive GBS isolates against 9 antimicrobial agents 
and results are presented in Table VIa, VIb, VIc. 
 
Table VIa: Susceptibility profile of GBS isolates using disc diffusion method (n=128) 
Antibiotics  No of susceptible (%) No of intermediate (%) No of resistant (%) 
Ampicillin 128 (100) - - 
Vancomycin 128 (100) - - 
Gentamicin-High level 128 (100) - - 
Ciprofloxacin 104 (71.0) 17 (13.2) 7 (5.4) 
Chloramphenicol 96 (65.6) 11 (8.5) 21 (16.4) 
Tetracycline  07 (5.4) 10 (7.8) 111 (86.7) 
 
Table VIa shows that all strains were 100% susceptible to ampicillin, vancomycin 
and to high level gentamicin; however 86.7% of the isolates were resistant to 
tetracycline, 16.4% to chloramphenicol and 5.4% to ciprofloxacin. The intermediate 
values were observed against ciprofloxacin (13.2%), chloramphenicol (8.5%) and 
tetracycline (7.8%). And when assimilated all the intermediate values to resistant; 
this gave the overall result of 94.5% of isolates resistant to tetracycline, 24.9% 
resistant to chloramphenicol and 18.6% resistant to ciprofloxacin. Figure 7 shows the 
result of susceptibility testing by Kirby Bauer.  
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Figure 6: Susceptibility testing results by disc diffusion method.  Isolate no 83 sensitive to ampicillin, 
vancomycin, ciprofloxacin, high-level gentamicin; but resistant to chloramphenicol and tetracycline.   
Table VIb: E – test MIC results for GBS isolates (n=128) 
Penicillin Erythromycin Clindamycin 
MIC 
µg/ml 
No of isolates 
(%) 
MIC 
µg/ml 
No of isolates 
(%) 
MIC 
µg/ml 
No of isolates 
(%) 
< 0.12 128 (100) < 0.25 101 < 1 106 
0.19 – 1 - 0.50 – 1 12 0.50 – 1 12 
> 1 - > 1 15 > 1 10 
 
All the isolates tested were 100% sensitive to penicillin with the MICs ranging from 
≤0.047μg/mL to ≥ 0.12μg/mL. 101/128 (78.9%) and 106/128 (82.8%) isolates were 
sensitive to erythromycin and clindamycin respectively. The MICs for erythromycin 
and clindamycin both ranged from ≤0.016μg/mL to ≥0.25μg/mL 
 
Resistant strains to erythromycin and clindamycin were observed in 21.1% and 
17.2% of the isolates, respectively. All erythromycin and clindamycin resistant 
isolates were screened for resistance genes. 
 
Table VIc: D-test (Double disk diffusion) results for GBS isolates (n=128) 
Antibiotics No of isolates Percentage 
(%) Erythromycin vs. clindamycin 
iMLSB positive 5 3.9 
cMLSB positive 20 15.6 
M phenotype positive 2 4.6 
L phenotype positive 2 0.7 
 
- iMLSB (MLSB-inducible methylation): Blunting defined as growth within the 
clindamycin zone of inhibition proximal to the erythromycin disk. See figure 9 
- cMLSB (MLSB-constitutive): Resistance to both erythromycin and clindamycin.  
- M phenotype: Resistance to erythromycin but susceptibility to clindamycin without 
blunting; indicated an efflux mechanism.  
- L phenotype: Resistance to clindamycin but susceptible to erythromycin 
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Figures 7 and 8 below illustrate the E-test result of one isolate, susceptible to 
clindamycin and the D-test result of one isolate susceptible to clindamycin and 
resistant to erythromycin, showing the D-zone.   
 
 
                                
Figure 7: susceptibility testing result by E-test  Figure 8: Susceptibility testing result by D-test 
isolate isolate no 1 sensitive to clindamycin      Isolate no 83. Observe the blunting showing D-
zone       
 
The overall result of the susceptibility testing of nine antibiotics tested and the 
number of positive pregnant women is presented in the graph below.  
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Figure 9: Overall results of nine antibiotics tested and the number of positive pregnant women. With 100 % of 
isolates sensitive to ampicillin, penicillin, vancomycin and high-level gentamicin; 21.1% of isolates were resistant 
to erythromycin, 17.2% resistant to clindamycin, 94.5% to tetracycline, 24.9% to chloramphenicol and 18.6% 
resistant to ciprofloxacin. 
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4.4 Molecular Identification  
Table VIIa and VIIb show the MICs of GBS isolates resistant to erythromycin and 
clindamycin and their phenotype values (D-shape) and resistant genes detected by 
multiplex PCR. The PCR products of isolates with resistant genes were distinguished 
by agarose gel electrophoresis and are presented in Figure 10 and 11 below. 
Table VIIa: MICs of erythromycin and clindamycin for resistant isolates and the 
screened genes for resistance (n=29)  
No MIC (µg/ml) D-shape MLS Genes  
 
Erythromycin  Clindamycin 
1 R-1 I-0.50 Negative cMLSB ermB 
2 R-3 I-0.75 Negative cMLSB linB + ermB  
3 I-0.75 I-0.75 Negative cMLSB linB + ermB 
4 I-0.50 S-0.047 Negative M phenotype mefA 
5 I-0.75 R-1 Negative cMLSB ermB 
6 R-4 I-0.50 Negative cMLSB ermB 
7 R-1 I-0.38 Negative cMLSB ermB 
8 I-0.75 R-1 Negative cMLSB ermB 
9 I-0.75 R-4 Negative cMLSB linB  + ermB 
10 R-4 R-7 Negative cMLSB ermB 
11 R-2 S-0.047 Positive iMLSB ermTR 
12 R-1.5 S-0.016 Positive iMLSB ermB 
13 I-0.75 I-0.50 Negative cMLSB linB + ermB 
14 R-8 I-0.38 Negative cMLSB ermB 
15 S-0.25 R-2 Negative L phenotype linB + ermB 
16 R-8 R-1 Negative cMLSB linB + ermB  
17 I-0.75 R-1 Negative cMLSB ermB 
18 R-3 I-0.38 Negative cMLSB ermB 
19 R-1 I-0.38 Negative cMLSB ermB 
20 R-1.5 S-0.25 Positive iMLSB ermB 
21 S-0.25 R-1 Negative L phenotype  linB +  ermB  
22 R-3 S-0.047 Positive iMLSB ermB 
23 I-0.50 I-0.75 Negative cMLSB linB + ermB 
24 R-2 R-8 Negative cMLSB ermB 
25 I-0.75 I-0.50 Negative cMLSB linB + ermB  
26 I-0.75 S-0.094 Negative M phenotype  ermB 
27 R-4 S-0.023 Positive iMLSB ermB 
28 I-0.50 R-1 Negative cMLSB linB + ermB 
29 I-0.75 I-0.50 Negative cMLSB linB + ermB  
 
R= Resistant   - iMLSB = MLSB-inducible methylation 
I= Intermediate  - cMLSB= MLSB-constitutive 
S= Susceptible  
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Table VIIb: Erythromycin-clindamycin resistance phenotypes and genotypes 
among GBS isolates (n=29) 
Phenotype Genotype 
 No of isolates Genes detected No of 
isolates 
Overall genes 
detected  
No of 
isolates 
iMLSB 5 ermB 4 ermB 
 
ermB + linB 
 
ermTR 
 
mefA 
 
linB 
15 
 ermTR 1 
cMLSB 20 ermB 11 11 
ermB + linB 9 
ermTR 0 1 
linB 0 
M phenotype 2 mefA 1 1 
ermB 1 
L phenotype 2 ermB + linB 2 0 
linB 0 
 
iMLSB  : E(R), Cd(S)   + D shape (ermB or ermTR) 
cMLSB  : E(R), Cd(R)  (ermB, ermTR, linB) 
M phenotype : E(R), Cd(S)   – D shape (efflux – mefA)  
L phenotype : E(S), Cd(R) (linB) 
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Fig 10: Agarose gel electrophoresis of Multiplex PCR 1 
Lane 8 : DNA Molecular Weight Marker Hyper Ladder
TM
 50bp (Bioline) 
Lane 14: Negative control (GBS ATTC 49743, susceptible to both erythromycin and clindamycin) 
Lane 3 : Presence of mefA gene, 348 bp (isolate no 60) 
Lane 5 : Presence of ermTR gene, 400bp (isolate no 83) 
Lane 1, 6, 7, 10, 11, 13, 15: Presence of ermB genes, 640bp (isolate no 15, 63, 65, 125, 148, 182, 183) 
Lane 2, 4, 9, 12, 16: Presence of ermB genes and linB genes, 944bp (isolate no 32, 57, 191,159 & 184) 
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Fig 11: Agarose gel electrophoresis of Multiplex PCR 2 
Lane 8 :     DNA Molecular Weight Marker HyperLadder
TM
 50bp (Bioline) 
Lane 7 :     Negative control (S. agalactiae ATTC 49743, susceptible to erythromycin and clindamycin) 
Lane 1, 3, 5, 6, 9, 10, 12, 13, 14, 15, 17: Presence of ermB genes, 640bp (isolate no 100, 116, 117, 121, 70, 74, 
68, 128, 86 & 129) 
Lane 2, 4, 11, 15, 16: Presence of ermB genes, 640bp and linB genes, 944bp (isolate no 110, 131, 99, 71 & 
104) 
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CHAPTER V 
DISCUSSION 
 
The primary objective of the present study was to isolate GBS from pregnant women 
and their babies at Dr. George Mukhari Academic Hospital (DGMAH). Secondly, to 
assess the antimicrobial susceptibility profile of those isolates to different antibiotics. 
Thirdly, to determine the incidence of antibiotic resistance in GBS isolates, and 
finally to investigate the mechanisms of antibiotic resistance in GBS isolates at 
DGMAH. 
 
From February 2012 to December 2012, a total of 413 pregnant women were 
recruited and 39 samples were collected from the babies born to colonized mothers. 
A multiple profile questionnaire was completed for each participant, to establish the 
participant’s demographic, obstetric and history of current pregnancy. Three swabs 
(RS, HVS, and LVS) were collected from each participant at recruitment and at 
delivery from the mothers; and ear and umbilical cord swabs from the babies at 
delivery; and all cultured onto selective media (CNA agar and Todd-Hewitt broth). 
GBS strains isolated were subjected to different tests of identification, including gram 
staining, catalase test, hemolytic activity, CAMP test, bile esculin and Latex 
agglutination test.  
 
Of the 413 specimens subjected to culture and identification, 128 (31%) were 
positive with GBS (Table IV). Of all the 39 samples collected from the babies born to 
colonized mothers, none of them were positive for GBS. In view of low numbers of 
specimens from babies, it is difficult to reach conclusion regarding prevalence of 
GBS in babies born to colonized mothers. 
  
The overall prevalence of GBS colonization among pregnant women of our findings 
is higher compared to the study conducted about 2 years ago in Johannesburg, 
South Africa, in which 21.5% of GBS was identified from the vaginal swabs only 
(Madzivhandila et al., 2011). This difference in colonization rates might be due to the 
characteristics of study participants and laboratory diagnosis method including site of 
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sample collection. In fact, culturing specimen from both the ano-rectum and vaginal 
introitus increases the likelihood of GBS isolation by 5% - 27% over vaginal culture 
alone (Badri et al., 1977; Dillon et al., 1982; CDC, 1996; Madzivhandila et al., 2011). 
 
Similar situation was also reported in GBS studies conducted elsewhere in the world.   
In Zimbabwe, Moyo et al., 2002 found the carrier rates of 31.6% and the rate of 
35.7% was reported by Mavenyengwa et al., in 2010.  Similar situation was also 
reported in Malawi, which 16.5% was found in Blantyre, Queen Elisabeth Hospital in 
2005 by Dzowela et al., and in 2011, in the same hospital, Gray et al., reported the 
rate of 21%. 
 
In Italy, Rosetti et al., in 1997 found the colonization rate of 12.3%; and Lambiase et 
al., when performing a series of investigations in the same country reported yearly 
increase in the colonization rates of vaginal-rectal cultures of 6.4% in 2005, 14.3% in 
2006, 37.5% in 2007 and 41.7% in 2008. Studies conducted in USA indicated a 
colonization rate of 25% (Berkowitz et al., 1990) and in 2007 Bergseng et al., found a 
colonization rate of 34.7%.  
 
Other different studies have reported different rates of GBS colonization, 29.5% in 
Québec – Canada (Bergeron et al., 2000), 23% in Tanzania (Joachim et al., 2009), 
12% in Finland (Lyytikäinen et al., 2003) and 7.6% in Argentina (Quiroga et al., 
2007). This  affirms that differences in colonization rates might be due to differences 
in genetics, in sampling and culturing techniques and generally to the geographic 
location or characteristics of the population investigated (Schrag et al., 2002; 
Edmond et al.,  2012). 
 
Considering the socio-demographic characteristics, similar findings to ours have 
been reported in studies conducted elsewhere (Manning et al., 2001; Schrag et al. 
2002; Dzowela et al., 2005; Mavenyengwa et al.,  2010 and Gray et al., 2011). The 
findings of our study show that most GBS positive pregnant women were from 
between the ages of 25 – 34 years old. This is similar to the mean age of 27.3 found 
by Dzowela et al., 2005 and 25.7 found by Mavenyengwa et al., 2010; but it is higher 
comparing to the study conducted by Manning et al., in 2001 which reported the 
mean age of 22 years.  This appears to be consistent with the findings by Narayanan 
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et al., 2006, that young and middle-aged women are at risk because of obstetric and 
gynecologic manipulations. 
 
There was significant difference between employment and GBS colonization. Our 
findings show that 59.3% of GBS positive women were unemployed and 39.8% were 
employed with 7.8% being skilled, 17.1% semi-skilled and 2.4% unskilled. The 
current study showed that the majority of GBS positive pregnant women were of the 
lower socio-economic groups. This is in agreement with what was reported by 
Schrag et al., in 2002, Chohan et al., in 2006 and Edmond et al., in 2012 that poor 
socio-economic status is a risk factor for GBS colonization.  
 
There was no significant difference between colonization and marital status of 
pregnant women. Our findings show that 53.1% of the GBS positive pregnant 
women were single, 21% were married and 24.2% were co-habiting. The educational 
level of GBS positive women ranged from below matric to tertiary level. At least 
11.7% of the GBS positive pregnant women reached the tertiary level; 59.3% matric 
level and 28.1% were below matric. With these percentages, it was difficult to find a 
scientific relationship between educational level, occupational status and GBS.  
 
In the current study of the 128 colonized women, 9.3% had history of stillbirths; this 
is higher when compared to 3.5% of stillbirths reported by Gray et al., in 2011; and 
almost 25% of pregnant women reported history of previous miscarriage. In our 
study, 12.1% of GBS colonized women had given birth before by caesarean section 
(C/S) and this is consistent with the 20% reported by both Lyytikainen et al., 2003 
and Gray et al., 2011. Of the 128 colonized women, 22 (17.1%) had vaginal 
discharge, 56 (43.7%) complained of flu like illness in early pregnancy and 6 (4.6%) 
had trauma in pregnancy. Overall, almost 40% of GBS positive women had poor 
obstetric history. This is almost similar to what was reported by Dzowela et al., 
(2005) which reported that 36.1% of pregnant women admitted previously had bad 
pregnancy outcomes. 
 
The HIV status of all participants in this study was recorded and there was no 
significant difference detected between GBS carriage (31%) and HIV positive women 
(40.6%). Of the 128 colonized women, 52 (40.6%) were HIV positive.  This was 
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higher when compared to 20.1% and 21.7% reported by Mavenyengwa et al. in 2010 
and Gray et al., in 2011, respectively. Our findings significantly differ from previous 
studies from elsewhere; Mavenyengwa et al., 2010 and Gray et al., 2011 on these 
conflicting findings concerning the relationship between persons infected with HIV 
being at increased risk of invasive GBS infections. This has raised conflicting views 
among scientists; some of whom have found that persons with HIV were at an 
increased risk of invasive GBS infections, but others have not detected any 
association between GBS disease and HIV infection (Mavenyengwa et al., 2010; 
Gray et al., 2011).  
 
During the course of our study, no maternal death was recorded but two neonatal 
deaths, three neonatal sepsis and one miscarriage were recorded, compared to the 
Malawian study in which 20 maternal deaths and 29 neonatal deaths were recorded 
(Gray et al., 2011). However, extreme cases were reported in our study, two babies 
were born with congenital abnormalities and (one with hydrocephalus).  One GBS 
pregnant mother was admitted in the hospital because there was no fetus movement 
for a week, and was found to have uterine fetus death; finally another GBS colonized 
woman, originally from Zimbabwe was reported to give birth to a macerated baby 
(fetus), and unfortunately swabs were not taken.  
 
In the present study, the susceptibility testing was performed on 128 GBS isolated 
from pregnant women against 9 antimicrobial agents. All strains were 100% 
susceptible to penicillin, ampicillin, vancomycin and high level gentamicin. Our 
findings are in agreement with the study conducted in Germany, in which Fluegge et 
al., (2004) found 100% of isolates sensitive to high-level Gentamicin, to penicillin, 
and to vancomycin. Similar findings were also observed in the USA by Manning et 
al., (2003) which showed 100% isolates sensitive to penicillin, to ampicillin and to 
vancomycin.  
This is also in agreement with an Ethiopian study where they found similar findings 
with 100% isolates sensitivity to ampicillin, to penicillin, to vancomycin and to 
gentamicin Musa et al. (2012). And in Argentina, Quiroga et al., 2008 found that 
100% of isolates were sensitive to ampicillin, to penicillin and to vancomycin.  
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Our findings are similar to the Zimbabwean study by Moyo et al., (2001) in which 
almost 100% of isolates were sensitive to penicillin (with only 2% were intermediate 
susceptible to penicillin), and 14% of isolates were resistant to erythromycin, 8% 
resistant to clindamycin and 100% of isolates were resistant to tetracycline.   
 
Our findings did not demonstrate isolates with an intermediate sensitivity or reduced 
MICs to penicillin using both disk diffusion and E-test methods compared to the 
findings by Simoes et al., (2004) in USA in which 19% of GBS isolates had an 
intermediate susceptibility to penicillin. Rouse et al., (1998) reported 10% of isolates 
having an intermediate susceptibility to penicillin; Liu et al (1997) in Taiwan reported 
15% of GBS isolated with intermediate susceptibility to penicillin. Kimura et al., 2008 
and Murayama et al., 2009 in Japan, reported the increasing MICs to penicillin in 14 
noninvasive isolates among adults and also alterations in a penicillin-binding protein 
(pbp 2x) were found in all of the isolates.  
In this study, 94.5% of the isolates were resistant to tetracycline, 24.9% resistant to 
chloramphenicol, 21.1% resistant to erythromycin, 18.6% resistant to ciprofloxacin 
and 17.2% resistant to clindamycin. 
 
The rate of erythromycin and clindamycin resistance was almost similar to the 
Canadian study by Desjardins et al. 2004, in which they found erythromycin and 
clindamycin resistant rates of 17% and 8% respectively; and this is also similar to the 
Tanzanian study conducted by Joachim et al., 2009 which reported GBS resistance 
rate of 17.6% and 13% erythromycin and clindamycin, respectively. The rate of 
erythromycin resistance (21.1%) found in our study is in agreement with the 
Malawian study by Gray et al., 2007 where they found erythromycin resistance rates 
of 21%. 
Our finding on erythromycin and clindamycin resistance was higher when compared 
to the Canadian study conducted by De Azavedo et al 2001, which reported 
erythromycin and clindamycin resistance rates of 8% and 4.5%. This current finding 
is lower when compared to the 38% and 21% of erythromycin and clindamycin 
resistant, respectively, reported by Gygax et al (2006). It is again far lower than the 
study conducted by Back et al. (2012) in the USA which  reported 50.7% of 
erythromycin resistance and 38.4% clindamycin resistance; and far lower than the 
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study conducted by DiPersio et al. (2006) which reported erythromycin and 
clindamycin resistance of 54% and 33%, respectively.  
 
The 94.5% tetracycline resistance rates found in our study is similar to the 96% 
reported by Gray et al., (2007), and also 85.2% reported by Betrui et al., (2003), 
86.8% by Azavedo et al., (2001), and 100% reported by Moyo et al. in 2001.  
Resistance to tetracycline might be explained by wide and indiscriminate use of 
these antibiotics worldwide. 
The molecular identification revealed that Multiplex PCR can be used as an effective 
screening method to detect different sequences important in GBS and to detect the 
major erythromycin and clindamycin resistance genes and also predict the 
phenotypic result of double disk diffusion test in the isolated GBS strains (Gygax et 
al., 2007; Gosiewski et al., 2012). 
 
In our study, the phenotypic testing by double disk diffusion revealed that 29 isolates 
were resistant to both erythromycin and clindamycin in which 20 (69%) isolates had 
harbored cMLSB, 5 (17.2%) had harbored iMLSB, the M phenotypes was present in 2 
(6.8%) isolates and the L phenotypes in 2 (6.8%). Our finding in phenotypic 
resistance by double disk diffusion was in agreement with the Canadian study by 
Desjardins et al. 2004 in which 47.2% had cMLSB resistance phenotype, 40% had an 
iMLSB resistance phenotype, and 12.7% of the isolates displayed M phenotypes. In 
Ireland, Khan et al., 2011 observed similar findings with 40% of isolates that 
harbored iMLSB, 36% had cMLSB, 24% M phenotype and 0% L phenotype 
 
The genotypic analysis by multiplex PCR (Table VIIb) shows that erythromycin and 
clindamycin resistance in GBS were mainly associated with ermB genes with 55% of 
isolates, ermTR genes harbored 3.4% and mefA genes 3.4% of the isolates and both 
ermB and linB genes together was harbored by 38% of the isolates. None of the 
strains carried both ermB and ermTR nor both mefA and erm nor linB alone. 
Our findings were consistent with a French study conducted by Fitoussi et al. 2001 in 
which ermB was found in 47% of isolates, ermTR genes in 45% of isolates and mefA 
gene in 6% of the isolates. None of the strains carried both ermB and ermTR or both 
mefA and erm genes too just like in our study.   
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There were two isolates which were phenotypically sensitive to erythromycin 
however had erm genes detectable on molecular testing. This may be due to erm 
gene not being expressed, but will require further studies to confirm the 
interpretation. And two isolates were resistant to clindamycin but no resistance 
mechanism was found. This situation could be explained by the fact that isolates 
may harbor mutations in genes coding for 23S rRNA. Similar situation was reported 
in Ireland where no resistance mechanisms were found in nine isolates (Khan et al.; 
in 2011).  
In South Africa, data to compare genetic mechanisms underlying erythromycin 
resistance in GBS was not obtainable. 
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CHAPTER VI 
CONCLUSIONS 
 
Our report shows that the colonization rate of GBS infections in pregnant women at 
DGMAH is 30.9% and may require review of antepartum screening policy.  
This study confirms the appropriateness of penicillin as still being the antibiotic of 
choice for treating GBS infections. However, the main concern was the increase in 
the resistance to the macrolides and clindamycin, used as alternative drugs for 
penicillin allergic patients. More GBS treatment options for penicillin allergic patients 
need to be explored. The methylation of targets encoded by ermB and ribosomal 
translocation encoded by linB genes were the commonest mechanisms of resistance 
observed and efflux pump mediated by mefA genes was also found among the 
isolates.  
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LIMITATIONS 
 Some of the women delivered out of our facility and it was difficult to reach 
them for follow up; and as a consequence there was a low number of babies 
in the study 
 During the molecular component of the study we could not find a positive 
control (ATCC strain) resistant to erythromycin and clindamycin to use. 
 
 
RECOMMENDATIONS 
 Although penicillin is still the antibiotic of choice, more GBS treatment options 
for penicillin allergic patients need to be explored 
 Constant surveillance is advisable and local statistics remain crucial for 
empirical antibiotic therapy 
 There is need for a comprehensive GBS incidence study to acquire strains for 
an in depth study of invasive isolates in South Africa.  
 More research studies need to be done in various areas and populations  of 
RSA to determine GBS colonization  
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APPENDIX 
APPENDIX A: CONSENT FORM 
Study title: Incidence and mechanism of antibiotic resistance of Streptococcus 
agalactiae isolates from pregnant women and their babies at Dr. George Mukhari 
Hospital 
You are asked to participate in a research study conducted by Department of Life and 
Consumer Science at UNISA and Department of Microbiological Pathology at Medunsa. It 
will form part of my Master degree. Your participation in this study is entirely voluntary. Read 
the information provided below. You are allowed to ask questions about anything you do not 
understand, before deciding whether or not to participate. 
Purpose of the study 
The purpose of this study is to determine the incidence and to investigate the mechanisms of 
antimicrobial resistance in GBS isolated from pregnant women and their newborns at Dr. 
George Mukhari Hospital, Ga-Rankuwa, Pretoria - South Africa. 
Procedures 
If you volunteer to participate in this study, you will be asked to provide us with your vaginal 
and rectal swabs as well as the umbilical/ear swabs from your neonates. The swabs will be 
analyzed by researchers in the laboratory for any antibiotic resistance you may have. You 
will also be required to complete the questionnaire which will require information about you 
and your baby.       
Potential risks and discomforts 
The only minor discomfort may be experienced during collection of lower vaginal as well as 
rectal swabs from you and umbilical/ear swabs from your baby, although this will be done by 
experienced Gynecologist and Pediatrician and research nurse.  
Participation and withdrawal 
You can choose whether or not to be in this study. If you volunteer to be in this study, you 
may withdraw at any time without consequences of any kind or loss of benefits to which you 
are otherwise entitled. There is no penalty if you withdraw from the study. In the event of 
physical and/or mental injury resulting from participation in this research project, UNISA 
does not provide any medical, hospitalization or other insurance for participants in this 
research study, nor will UNISA provide any medical treatment or compensation for any injury 
sustained as a result of participation in this research study, except as required by law. 
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Potential benefits to subjects and/or to society 
Participation in this research will help you to know if you/your neonate have developed any 
resistance toward antibiotics used for Group B streptococcus infection. This will enable the 
doctor to provide you with alternative treatment in case you are infected. 
Being part of this study will also help us to have knowledge of antibiotic that are resistance to 
GBS infection at GMH Ga – Rankuwa. This research will also enable the government to 
work towards providing alternative treatment and preventions strategies. 
Confidentiality 
Any personal information that is obtained in connection with this study and that can be 
identified with you will remain confidential and will be disclosed only with your permission or 
as required by law. Confidentiality will be maintained by using code name instead of your 
real name on samples. 
Declaration 
I have read the information about the proposed study and was provided with the opportunity 
to ask questions and given adequate time to rethink the issue. The aim and objectives of the 
study are sufficiently clear to me. I have not been pressurized to participate in any way. 
 
I understand that participation in this study is completely voluntary and that I may withdraw 
from it at any time and without supplying reasons.  This will have no influence on the regular 
treatment that holds for my condition neither will it influence the care that I receive from my 
regular doctor. 
I am fully aware that the results of these this study is for research purpose only. I agree to 
this, provided my privacy is guaranteed. 
 
I hereby give consent to participate in this study  
 
...........................................................        ........................................................ 
Name of participant                                                        Signature of participant 
 
................................    ....................................    ................................................ 
Place.                             Date                                Signature of Witness 
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APPENDIX B: QUESTIONNAIRE – PART I 
Personal information of Patient (Mother) 
Full names…………………………..Surname……………………………….….. 
Languages…………………………..Date of Birth…………………………....…. 
Race   : Black……….Coloured….........Indian……….White……               
Marital status  : Single .......Married…......Divorced.......Widowed....Cohabiting... 
Residential address : Urban……….Semi-urban….…Rural…………………… 
Contact no………………………………………………………………………………..… 
 
Education History:   Primary school…… Secondary school…. Diploma…. Degree…… 
 
Medical Information 
Chronic illness 
Are you suffering from any chronic illness?                  Yes…………….No……..… 
If yes, which chronic illness…………………………………………………………..  
Pregnancy information 
How old is your pregnancy? 
Less than 3 months……3-6 months……7-9 months…… More than 9 months 
Is this your first pregnancy?                         Yes……………..No…………………...  
If No how many pregnancies did you previously have? …………................. 
Information about delivery 
Have you had any miscarriage before?                   Yes…...No……………………… 
Have you had any still birth before?            Yes…...No………………………                    
From the first month of your pregnancy till now, have you had any urinary tract infection?                  
Yes……..No……………………. 
Did you have a vaginal discharge requiring treatment during the current pregnancy?   
                      Yes…….No…………..……..……          
Details of mother at delivery………………………………………………………….………….. 
Place of Delivery                                         Hospital __        Clinic __           Home __ 
Type of delivery                                            NVD      __          C/S- __ 
If other please specify _________________________________ 
Time between rupture of membrane and delivery ___________ 
Temperature _________________________________________ 
Antibiotic treatment ___________________________________ 
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APPENDIX C: QUESTIONNAIRE – PART II 
Details of the baby at delivery 
 
Alive                Yes  __  No __ 
                                                                        
Stillbirth                                             Fresh   __    Macerated     __ 
                                                                    
Congenital abnormality                              Yes       __    No    __ 
Specify (If yes) _____________________________________ 
 
Gestational age (weeks) at delivery           ______ 
                                                                 
Swabs collected 
(Umbilicus, ear)                           Yes        __     No   __ 
                                                       
Cord blood collected                               Yes    __       No __ 
 
Fetal: Apgar:                                           1 min ……  5 min …… 
Mass:                                                          Kg: ………. 
 
Resuscitation required:                              Yes __     No __ 
                         
ii) Details of the mother at delivery                      
Place of Delivery                                    Hosp. __       Clinic __          Home 
__ 
                                                            
Type of delivery                   NVD  __      C/S __        Forceps 
__ 
Collect                  vaginal swab  __       rectal swab__      venous blood 
__ 
 
Time between rupture of membrane and delivery ___________ 
 
Temperature ________________________________________ 
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Antibiotic treatment ___________________________________
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APPENDIX D: DATA COLLECTION SHEET 
      
Study no…………..........      Specimen type……….……………         Date…………. 
1. CULTURE 
 
Colony Count 
 
Quantity growth +, ++, +++ 
RS LVS HVS 
CNA    
Todd Hewitt Broth    
          Initials……………Date……………….. 
 
2. IDENTIFICATION 
RESULTS 
GBS RS LVS HVS 
Hemolytic Activity     
Catalase Test     
Gram Stain     
Bile Esculin    
Agglutination (STREPTEX)    
CAMP test    
                                                                     Initials……………Date………….. 
 
3. ANTIBIOTIC SUSCEPTIBILITY 
 
GBS Peni Erythro Clinda Ampi  Vanco Genta chlora Tetra Cipro 
Results Disc D.          
E-Test          
D-Test          
 
          Initials…………… Date…………….. 
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APPENDIX E: GBS WORK SHEET   
 
DATE  
OF 
COLLE 
CTION  
 
STUDY 
No 
TYPE OF 
SAMPLES 
TIME 
RECEIVE
D 
in Lab 
CULTURE RESULT IDENTIFICATION 
 
 
STO
RE 
Y/N 
R
S 
L
V
S 
H
V
S 
BLD RS HVS LVS HEMO 
LYTIC 
ACTIV
ITY 
CATA 
LASE   
TEST 
 
MICRO
SCOPY 
STREP 
TEX 
CAMP 
Test 
 
C
N
A 
T
H
B 
C
N
A 
T
H
B 
C
N
A 
T
H
B M B 
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
                    
 
RS: Rectal Swab;   LVS: Low Vaginal Swab;   HVS: High Vaginal Swab;   BLD: Blood;   CNA: Colistin Nalidixic 
Acid agar; THB: Todd Hewitt Broth; M: Mothers;   B: Babies;   
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APPENDIX F: ANTIBIOTIC SUSCEPTIBILITY TESTING – PROTOCOL  
Materials & Media required 
The SOP was developed. Mueller-Hinton agar supplemented with 5% sheep blood, Blood 
agar or CNA, normal saline, McFarland standards, sterile loops and swabs, sterile forceps, 
CO2 incubator, antibiotics (discs & E-test), antibiotic disc dispensers, quality control strains, 
ruler or caliper for measuring zone size, CLSI guidelines 2012  
Methods 
1. Label the blood agar plates with study identification numbers. 
2. Open aseptically the cryovial (microbank) with GBS isolates, and using a sterile needle or 
forceps, remove one bead and directly streak onto blood agar (or CNA)  
3. Incubate at 370C in 5% CO2 environment for 20-24h,  
4. Perform gram stain, catalase, streptex or CAMP test for purification of the organism. 
5. Select a pure colony from overnight positive GBS plates and suspend into normal saline  
6. Adjust the culture until the turbidity is equivalent to the 0.5McFarland standard 
7. Inoculate the culture (using a sterile swab) onto Mueller-Hinton agar (+5% sheep) blood 
plates 
8. Place antibiotics onto agar using dispenser or sterile forceps. 6 discs was placed into 1 
plate (100mm apart); Place erythromycin and clindamycin discs 12mm distant to enable 
demonstration of MLS resistance phenotype 
9. Place MIC strips (E-tests) in 1 plate.  
10. Incubate at 370C for 20-24h in 5% CO2 environment  
11. Read the plate the following day; use caliper or ruler to measure the zone of inhibition in 
mm, and interpret the results by using the CLSI guidelines 2012. 
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APPENDIX G: DNA EXTRACTION PROTOCOL  
 (ZYMO RESEARCH – USA– DNA Mini-KIT – Inqaba   Biotec, SA) 
Product Contents: ZR BashingBead Lysis Tubes (50), Lysis Solution (40ml), Bacterial DNA 
Binding buffer (100ml), Bacterial DNA Pre-wash Buffer (15ml), Bacterial DNA wash buffer 
(150ml), Elution buffer (10ml) , Zymo-Spin IV spin filters/ Orange Tops (50), Zymo-Spin IIC 
Columns (50), Collection Tubes (150).  
For optimal performance, add beta-mercaptoethanol/ optional (supplier) to the Bacterial DNA 
Binding buffer to a final dilution of 0.5% (v/v) i. e, 500µl per 100 ml. 
STEPS 
- Add 200µl of sterile water or isotonic buffer (e.g. PBS)  into 1.5ml microcentrifuge 
tube  
- Suspend bacterial cell (from overnight growth ) into the above water  
- Add 50-100 mg (wet weight/colony) of the suspension into ZR BashingBead Lysis 
tubes 
-  Add 750 µl of Lysis Solution to the tube  (ZR BashingBead Lysis tubes) 
- Secure in a bead beater fitted with a 2ml tube holder assembly (e.g. Disruptor Genie) 
- Process at maximum speed for 5 min 
- Centrifuge the ZR BashingBead Lysis Tubes in microcentrifuge at 10,000 RPM for 1’ 
- Transfer up to 400 µl supernatant to a Zymo-Spin IV Spin Filter (orange top) in 
Collection Tube. Centrifuge at 7,000 x g (7,000 RPM) for 1min 
- Add 1200 µl of Bacterial DNA Binding buffer to the filtrate in the collection tube from 
step above 
- Transfer 800 µl of the mixture from step above to a Zymo-Spin IIC column in a 
collection tube. Centrifuge at 10,000 x g (10,000 RPM) for 1min 
- Discard the flow through from the collection tube and repeat the above step 
- Add 200 µl DNA Pre-Wash Buffer to the Zymo-spin IIC column in a new collection 
tube 
- Centrifuge at 10,000 x g (10,000 RPM) for 1min 
- Add 500 µl Bacterial DNA Wash Buffer to the Zymo-spin IIC column. Centrifuge at 
10,000 x g (10,000 RPM) for 1min 
- Transfer the Zymo-Spin IIC column to a clean 1.5 ml microcentrifuge tube  
- Add 100 µl DNA Elution Buffer directly to the column matrix. 
- Centrifuge at 10,000 x g (10.000 RPM) for 30 seconds to elute the DNA 
The Ultra-pure DNA is now ready for use in your experiments 
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